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Abstract
Many pharmacologically active compounds are of amphiphilic (or hydrophobic) nature. As a result, they tend to self-
associate and to interact with biological membranes. This review focuses on the self-aggregation properties of drugs, as well
as on their interaction with membranes. It is seen that drug^membrane interactions are analogous to the interactions between
membranes and classical detergents. Phenomena such as shape changes, vesiculation, membrane disruption, and
solubilization have been observed. At the molecular level, these events seem to be modulated by lipid flip-flop and
formation of non-bilayer phases. The modulation of physicochemical properties of drugs by self-association and membrane
binding is discussed. Pathological consequences of drug^membrane interaction are described. The mechanisms of drug
solubilization by surfactants are reviewed from the physicochemical point of view and in relation to drug carrying and
absorption by the organism. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Many pharmacologically active compounds are
amphiphilic or hydrophobic molecules, which may
undergo di¡erent kinds of association, and whose
site of action in the organism frequently is the plas-
ma membrane. Even if their target is intracellular,
the interaction with this ¢rst barrier plays a funda-
mental role.
Amphiphilic compounds bear an ionic (zwitter-
ionic, anionic or cationic) or non-ionic polar head
group and a hydrophobic portion. In aqueous me-
dium, they are able to organize themselves as mi-
celles, bilayers, monolayers, hexagonal or cubic
phases. The spatial separation between the polar
and non-polar moieties, as well as the molecular
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shape [1] and the hydrophilic^hydrophobic balance
(HHB) [2], determines their tendency to form the
di¡erent structures, which eventually can be inter-
converted as a function of pH, temperature, ionic
strength, concentration.
Surfactants (detergents) tend to associate as mi-
celles; in these structures the hydrophobic portion
is sequestered from the highly polar aqueous medium
by a surrounding, approximately spherical, shell
formed by the polar or ionic head groups. Classical
surfactants have been extensively studied, both in
terms of their self-aggregation properties and for
their capacity to interact with model and biological
membranes, promoting lysis, extraction of speci¢c
components (proteins or lipids), and ultimately, sol-
ubilization [3,4].
Micelle formation can be envisioned as a stepwise
process, characterized by a series of equilibria and
equilibrium constants or as a phase separation (all
or none) process such that, once a critical concentra-
tion (the critical micellar concentration, cmc) is
reached, further addition of the surfactant will result
in aggregation [5]. Several authors have discussed the
energetics of micelle formation [1,6^8]. Micelles are
characterized by physicochemical parameters such as
the cmc, aggregation number (N), particle size, HHB.
This is a very simpli¢ed picture, since even for typical
micelle-forming systems, pre-micellar aggregation
has been described [9,10]. Moreover, micelles are po-
lydisperse and the aggregation number represents the
most probable one within a distribution [5]. Micellar
shape is usually assumed to be spherical, but micelles
are known to grow with increasing detergent concen-
tration, becoming cylindrically shaped [5].
Micelles are highly dynamic structures, the equilib-
rium between monomer and aggregate being a fast
process (lifetime of the order of microseconds). The
dynamic nature of these aggregates is also re£ected
in the motional properties of the monomers within
the micelle. They can rotate about their long molec-
ular axes [9,10], di¡use laterally along the micellar
surface [11], and, when formed by alkyl chain-con-
taining surfactants, the chains, being highly £exible,
can undergo segmental motion [9,10]. In comparison
with other aggregates, such as bilayers, micelles are
more loosely packed and less stable [12].
Because of their strong tendency to aggregate, al-
kyl chain-containing surfactants seem to associate
according to the phase separation model. Normally,
these micelles exhibit N between 50 and 200 [5]. Oth-
er detergents display a di¡erent aggregation behav-
ior. A classical example is that of bile salts (BS),
whose mechanism of micelle formation corresponds
to a stepwise association [13]. N is usually much
smaller than those of micelles formed by alkyl chain
detergents. BS micelles are formed by juxtaposition
of hydrophobic domains of adjacent molecules. The
aggregation of BS is complex; for additional infor-
mation, the reader is referred to the chapter by Kra-
thovil in this issue and references therein.
Surface active drugs of quite di¡erent chemical
structure are reported to self-associate and bind to
membranes, causing disruption and solubilization, in
a detergent-like manner.
Classes of amphiphilic drugs include phenothiazine
[14^24] and benzodiazepine [25] tranquilizers, analge-
sics [26], peptide ([27] and references in Section 3.3)
and non-peptide [28,29] antibiotics, tricyclic antide-
pressants [30^32], antihistamines [33], anticholiner-
gics [34], L-blockers [35], local anesthetics (LA)
[12,36^39], non-steroidal antiin£ammatory drugs
[40], anticancer drugs [41]. Many of these drugs con-
tain one or more (condensed or not) aromatic nuclei,
while others are of peptide nature. Table 1 lists the
cmc and aggregation number (under speci¢c condi-
tions) of some commonly used non-peptide drugs.
Fig. 1 presents structures of drugs that will be fre-
quently referred to in this paper.
The literature on surface active drugs is vast and
multifocused, rendering it a di⁄cult task to elaborate
a comprehensive review on the subject. In view of
this, we will restrict the present article to examples
focusing on compounds and topics that have been
largely studied. A great deal of data on the surface
active properties of drugs can be found in the book
by Attwood and Florence [45], and other reviews
[46^48].
We will focus on the surface active properties of
drugs from the point of view of: (i) their self-aggre-
gation properties; (ii) their interaction with mem-
branes; (iii) the use of classical surfactants as solu-
bilizers of amphiphilic and hydrophobic drugs and
their use in drug delivery. Some shorter topics (see
Sections 7^9) will also be discussed.
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2. Self-association of amphiphilic drugs
The aggregation of surface active drugs follows the
same principles as classical detergents. While some
drugs display the ability to self-associate forming
closed, micelle-like structures, others aggregate by
continuous stacking [48]. When micelles are formed,
their aggregation number usually is small (Table 1).
Drug self-association is also temperature-, ionic
strength-, and pH-dependent. The cmc of a series
of piperazine-containing drugs increased and N de-
creased with decreasing pH, due to protonation of
Table 1
Micellar properties of some non-peptide surface active drugs in water
Class Drug cmc (M) N Ref.
Analgesics Dextropropoxyphene 1.0U1031 7 [45]
Antibiotics Actinomycin D 1.0U1034 ^ [45]
Penicillin G 2.5U1031 ^ [45]
Streptomycin 9.0U1035 ^ [45]
Sodium fusidate 3.6U1033 ^ [44]
Anticholinergics AdiphenineWHCl 8.2U1032 10 [45]
ChlorphenoxamineWHCl 4.5U1032 13 [45]
OrphenadrineWHCl 9.6U1032 7 [45]
Penthianate methobromide 2.2U1031 6 [33]
PiperidolateWHCl 8.2U1032 12 [45]
Antifungal polyenes Amphotericin B 6.0U1037 ^ [240]
Nystatin 3.0U1036 ^ [42]
Antihistamines BromodiphenylhydramineWHCl 5.4U1032 11 [33]
ChlorcyclizineWHCl 1.27U1031 3 [45]
DiphenhydramineWHCl 9.0U1032 9 [33,45]
DiphenylpyralineWHCl 4.0U1032 9 [33,45]
ThenyldiamineWHCl 1.0U1031 3 [45]
TripelennamineWHCl 1.2U1031 3 [45]
Antihypertensives (with L-blocking action) AcetobutololWHCl 1.7U1031 4 [45]
OxprenololWHCl 1.7U1031 3 [45]
PropranololWHCl 1.0U1031 12 [33,45]
General anesthetics Thiopental 7.0U1033 ^ [62]
Local anesthetics DibucaineWHCl 6.6U1032 ^ [104]
1.1U1032 9 [37]
StadacaineWHCl 7.6U1032 17 [45]
TetracaineWHCl 1.3U1031 7 [39,43]
6.0U1032 ^ [12,36]
Phenothiazines ChlorpromazineWHCl 1.9U1032 11 [45]
2.2U1032 12 [18]
PromazineWHCl 3.6U1032 11 [45]
1.2U1032 ^ [16]
PromethazineWHCl 4.4U1032 9 [45]
5.8U1032 12 [18]
ThioridazineWHCl 5.9U1033 8 [45]
1.5U1033 ^ [16]
Tri£uoperazine 4.2U1035 ^ [104]
Tri£uopromazine 4.5U1033 ^ [16]
Thioxanthene tranquilizers Flupenthixol 8.5U1033 19 [45]
Tricyclic antidepressants AmitriptylineWHCl 3.6U1032 7 [45]
ButriptylineWHCl 4.2U1032 9 [45]
ClomipramineWHCl 2.2U1032 6 [45]
DesipramineWHCl 4.9U1032 7 [45,62]
ImipramineWHCl 4.7U1032 8 [18,45]
NortriptylineWHCl 2.3U1032 4 [45]
BBAMEM 77971 10-11-00 Cyaan Magenta Geel Zwart
S. Schreier et al. / Biochimica et Biophysica Acta 1508 (2000) 210^234212
the second nitrogen atom of the drugs’ piperazine
ring [49].
We will describe below some properties of two well
studied families of drugs, the phenothiazine tranquil-
izers and the polyene antibiotics.
2.1. Phenothiazine tranquilizers
Phenothiazines aggregate in a micelle-like manner,
N being of the order of 6^15 [14^24]. The drugs were
seen to form pre-micellar aggregates [23]. The phe-
nothiazine ring system (Fig. 1, chlorpromazine) is V-
shaped about an axis from the N to S atoms with an
internal angle of about 155‡ [50]. Nuclear magnetic
resonance (NMR) data suggest a concave-to-convex
stacking of molecules within the pre-micellar and
micellar aggregates, with the alkyl side chains on
alternate sides of the stacks [16,51]. It was proposed
that micelles are formed by several short stacks hy-
drophobically bonded together, generating roughly
symmetrical systems [16]. This mechanism would al-
low for the formation of higher aggregates and
would explain the larger values of N calculated for
drugs from this family [52,53].
The cmc of phenothiazine micelles decreases and N
increases with increasing electrolyte concentration.
At higher salt concentrations, a spherical-to-rod
transition occurs. The cmc decreased and N in-
creased in the order F36Cl36Br36 I3 [16]. At
higher I3 concentrations and in the presence of phos-
phate, phase separation was observed. The order
of the e¡ects correlated with the position of the
ions in the Hofmeister series. The e¡ects were dis-
cussed in terms of an interplay of factors including
the a⁄nity of the counterion for the aggregate, coun-
terion hydration energy, and ion e¡ects on water
structure.
The cmc of chlorpromazine (CPZ) is pH-sensitive,
increasing with decreasing pH. Above the cmc, CPZ
micelles undergo a concentration-, temperature-, and
pH-dependent transition leading to phase separation,
which is followed by a sudden increase in light scat-
tering. Spin label electron paramagnetic resonance
(EPR) spectra indicated an increase in intramicellar
compactness at higher pH, due to a decrease in head
group repulsion [17].
Aggregation also a¡ects the apparent pK (pKapp)
of ionizable compounds. The pKapp of tri£uoperazine
(TFP) decreased with increasing drug concentration
[49]. pK shifts are also observed upon binding of
drugs containing ionizable groups to bilayers or mi-
celles (see Section 4.1).
Fig. 1. Structures of some surface active drugs discussed in this paper.
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2.2. Polyene antibiotics
Self-association also occurs in another class of
drugs, the polyene antibiotics, used against mycotic
infections. One member of this family, amphotericin
B (AmB), is widely used in the treatment of systemic
infections (to which immunodepressed patients are
very sensitive), in spite of its toxic e¡ects, the most
serious being nephrotoxicity. Because of its clinical
importance, AmB has been one of the ¢rst drugs
used in patients in liposomal form, which greatly
decreases its toxicity.
AmB (Fig. 1) is highly water-insoluble (V1037 M)
and its aggregation behavior is extremely complex.
The toxic and therapeutic e¡ects of AmB were seen
to correlate with the particle size of the intravenously
injected antibiotic [54], implying that these e¡ects are
modulated by its aggregation state. The long time
used clinical preparation (Fungizone) consists of a
1:2 (mol:mol) AmB:deoxycholate (DOC) complex.
The circular dichroism (CD) spectra of this prepara-
tion in aqueous ethanolic solution suggested that
AmB forms helical aggregates [55]. The aggregation
properties of Fungizone were examined by spin label-
ing [56] and by quasielastic light scattering [57].
These studies indicated that Fungizone consists of
large aggregates rather than small mixed micelles
(MM), as is usually implied in the literature, and
that the system is quite unstable, ultimately decom-
posing into solid AmB and DOC micelles. The ki-
netics is faster in the presence of salt. At high con-
centration, the mixed aggregates coexist with pure
DOC micelles that serve as a pool of DOC, and
stabilize the mixed aggregate. Dilution below DOC’s
cmc leads to a faster loss of aggregate stability. The
particle size increased with decreasing AmB-DOC
concentration, probably due to loss of DOC from
the aggregates.
In aqueous solution the drug has been found to
exist as a mixture of various species: monomers and
soluble, as well as insoluble, aggregates, whose con-
centration depends on factors such as total antibiotic
concentration, method of preparation, and even the
concentration of the stock solution [58]. In addition,
temperature has pronounced e¡ects: heating to 50^
60‡C causes formation of ‘super-aggregates’ [59]. The
aggregation state of AmB also modulates the kinetics
of its autoxidation [59^61].
2.3. Surface activity and drug penetration through the
blood^brain barrier
Recently Anna Seelig and coworkers have devised
a method to predict the ability of drugs to cross the
blood^brain barrier (BBB) based on the drug’s sur-
face active properties [62,63]. The surface activity of
drugs was quanti¢ed by their Gibbs adsorption iso-
therms in terms of three parameters: the onset of
surface activity, the cmc, and the surface area re-
quirement of the drug at the air^water interface. By
plotting the cmc as a function of the concentration
required for the onset of surface activity (Co), three
regions could be identi¢ed: the low cmc, low Co
region corresponded to very hydrophobic drugs, un-
able to cross the BBB because of their strong binding
to the membrane; the intermediate region encom-
passed less hydrophobic drugs, that can di¡use
through the BBB; the drugs in the third region are
relatively hydrophilic and only cross the BBB when
applied at high concentrations. Similar results were
obtained in plots of cmc vs. 1/Kaw, Kaw being the
drug’s air^water partition coe⁄cient, a parameter
that correlated with Co. Over 50 drugs were analyzed
according to these criteria and their location in these
plots was in agreement with their ability to cross the
BBB.
3. Surface activity e¡ects in amphiphilic
drug^membrane interactions
Amphiphilic drugs interact with membranes, mod-
el and biological, causing a variety of e¡ects. The
literature in this ¢eld is very large. Considerable ad-
vances in the understanding of the e¡ect of drugs on
the structural and dynamical properties of membrane
components have been achieved through the use of
spectroscopic (EPR, NMR, £uorescence, Fourier
transform infrared, CD) and other biophysical (X-
ray and neutron di¡raction, di¡erential scanning cal-
orimetry (DSC), titration calorimetry, monolayers)
techniques. We will not discuss here the e¡ects of
drugs on the degree of order and mobility of mem-
brane lipids. Rather, we will focus on phenomena
that can lead to membrane disruption and even sol-
ubilization, and that often are responsible for the
drugs’ toxic e¡ects. Literature will be presented on
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phenomena such as drug-induced lipid £ip-£op, in-
terdigitation, and formation of non-lamellar phases
that could be related, at the molecular level, to the
mechanism of the disruptive (surfactant) e¡ects of
drugs,
A theoretical analysis of the e¡ects of drugs on
lipid bilayers has been provided by Mouritsen et al.
[64,65]. Assuming that drugs insert into membranes
as interstitial components, it was shown that they
a¡ect the organization and thermotropic properties
of the lipids. Computer simulations indicated that
partitioning drugs accumulate heterogeneously in
the membrane, higher concentrations being attained
at the interface between gel phase and liquid crystal
domains. As a consequence, local concentrations
may be much higher than in the bulk aqueous phase
or even in other regions in the lipid bilayer. This
possibility should be borne in mind when discussing
drug e¡ects on membranes, especially in the context
of the present article, where surface active properties
of drugs are in focus. The microscopic description of
drug insertion into bilayers provided by the work of
Mouritsen and colleagues suggests that bilayer dis-
ruption by drugs could be modulated by micelle-like
aggregates or other non-bilayer phases whose forma-
tion is induced by a local increased concentration.
Early work [46] attempting to evaluate the surface
activity of drugs made use of their interaction with
lipid monolayers at an air^water interface. Some pio-
neering studies along these lines have been performed
by Skou [66] on LA. A classical review by Seeman
[67] describes his and other studies on the membrane
action of pharmacologically active compounds.
The conditions favoring membrane disruption usu-
ally imply a high drug:lipid molar ratio. This does
not imply that such concentrations are not achieved
in the organism since it has been shown that the
liver/plasma ratios of tricyclic antidepressants are of
Fig. 2. Scheme of possible events taking place with an amphiphilic surface active drug starting from the solid. The processes corre-
sponding to the equilibria are: 1 ^ solubilization; 2 ^ monomer^aggregate equilibrium; 3 ^ monomer binding to the membrane; 4 ^
aggregated drug binding to the membrane; 5 ^ membrane solubilization. Upon saturation drug molecules leave the membrane carry-
ing membrane components, lipids and proteins. The ks represent rate constants. The possible events resulting from drug^membrane in-
teractions prior to solubilization are listed in the scheme.
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the order of 20^100:1 [68]. At high drug:lipid ratios
(global, or as discussed above, local) the surface ac-
tive properties of the drug come into play and one
would expect processes similar to those operating
with classical detergents. In the latter case, removal
of membrane components occurs after the membrane
becomes saturated and the detergent concentration in
the aqueous phase reaches the cmc [69,70]. Further
addition leads to removal of membrane components,
giving rise to lipid^detergent, protein^detergent, or
lipid^protein^detergent MM. Fig. 2 depicts the pos-
sible steps involved in this mechanism. A model pro-
viding a qualitative and quantitative analysis of this
process was developed by Lichtenberg [69], and has
been applied by Gon‹i and coworkers to the action of
several detergents and detergent-like molecules [71].
In many studies of drug-induced membrane dis-
ruption, the state of the drug in the aqueous phase
has not been examined. Nevertheless, since this pro-
cess usually takes place at high drug:lipid ratios, it is
conceivable that the drug would be aggregated in the
aqueous phase.
3.1. Drug-induced membrane phenomena: shape
changes, lipid £ip-£op, non-bilayer phase
formation, vesiculation, solubilization
A very commonly used model for studies of am-
phiphilic drugs is the red blood cell (RBC). Under
hypotonic conditions, many drugs display a biphasic
behavior in RBC: while low concentrations protect
the membrane, higher concentrations produce he-
molysis [67], probably by the mechanism depicted
in Fig. 2. This biphasic behavior was also observed
with classical surfactants [72,73]. The hypotonic he-
molytic test has become a classical tool for studying
drug^membrane interactions. Drugs exhibiting bi-
phasic behavior are: LA, tranquilizers, antihist-
amines, antiin£ammatory drugs, antiarrhythmics,
sedatives, narcotics, polyene antibiotics, vitamin A,
steroids, peptides [67]. At the onset of the lytic phase,
in general, initially the permeability of small solutes
and ions, like K, increases. As a result of the col-
loid^osmotic imbalance, other solutes permeate and,
ultimately, large holes are formed causing the loss of
cell contents, including proteins.
In the early 1970s, evidence started to accumulate
for the asymmetric distribution of components in the
outer and inner monolayers of biological membranes
[74]. It was also known that drugs caused shape
changes when added to erythrocytes. Two main types
of changes occurred: the biconcave disk-shaped cells
were converted to a crenated form (echinocytes) or
to an invaginated or cupped form (stomatocytes).
Moreover, Deuticke [75] had observed that most
crenation inducers were anionic (free fatty acids, bar-
biturates), while cup formers were essentially cationic
(phenothiazines, LA). Based on these observations,
Sheetz and Singer [76] formulated their bilayer cou-
ple hypothesis, i.e. they suggested that the two halves
of the membrane could respond di¡erently to pertur-
bations while remaining coupled to each other. It
was suggested that if expansion of one monolayer
in the plane of the membrane occurred with respect
to the other, the two layers would still remain in van
der Waals contact with each other, leading to various
functional consequences, including cell shape
changes. The authors proposed that cup formers
would distribute preferentially into the cytoplasmic
half of the bilayer, causing it to expand, and leading
to invagination. Crenators, on the other hand, would
intercalate preferentially in the outer monolayer, ex-
panding this region and inducing echinocytosis. This
behavior would be driven by the higher concentra-
tion of negatively charged phospholipids in the inner
monolayer. At higher concentrations, both types of
compounds caused the RBC to become spherical and
lyse.
These ideas were tested by examining the interac-
tion between RBC and drugs carrying an ionizable
tertiary amine, as well as their quaternary ammo-
nium counterparts. Scanning electron micrographs
showed that, while the quaternary ammonium ion
methochlorpromazine acted as a crenator, CPZ acted
as a cup former [76].
The bilayer couple hypothesis exerted great in£u-
ence and many authors have interpreted changes in
membrane shape in terms of preferential location of
incorporated amphiphilic solutes. A theoretical veri-
¢cation of the bilayer couple hypothesis was pre-
sented by Iglic and coworkers [77].
With the discovery by the group of Devaux [78]
that lipid £ip-£op rates in biological membranes are
much faster than in model systems, studies were
undertaken to verify whether drug-induced RBC
shape changes were related to changes in lipid distri-
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bution across the two halves of the membrane. Ros-
so et al. [79] and Schrier et al. [80] demonstrated that
both vinblastine and CPZ caused time and concen-
tration-dependent RBC stomatocytosis, as well as
lipid scrambling. Later, Chen and Huestis [81] pro-
posed that, while CPZ induces lipid redistribution
over extended time periods, which may mediate the
complex morphological transformations observed,
the early stomatocytic response elicited by addition
of CPZ is not due to lipid reorganization.
Another phenomenon known to destabilize the bi-
layer structure is the formation of non-lamellar
phases. The bilayer to hexagonal II (HII) phase tran-
sition has been implied in the mechanism of mem-
brane fusion [82] and is known to depend on lipid
nature, shape, temperature, and on the presence of
additives, such as Ca2 ions, and drugs. The local
formation of non-lamellar (HII) phases in a mem-
brane could give rise to a region that would destabi-
lize the bilayer, creating an eventual site for the ini-
tiation of cell disruption. In work dealing with
several kinds of amphiphiles, Isomaa et al. [83] sug-
gested that the observed shape changes would be due
to the formation of non-bilayer intrabilayer phases.
In addition, transmembrane lipid redistribution was
also observed. Indeed, the induction of HII phase
formation by the peptide antibiotic gramicidin A in
RBC was seen to occur under the same conditions
that favored lipid £ip-£op [84].
Lipid £ip-£op in RBC membranes was also in-
duced by AmB [85], LA [85], gramicidin A [86], ali-
phatic [87] and aromatic [88,89] alcohols. Flip-£op of
an anticancer drug, doxorubicin, was also shown to
occur across erythrocytes, as well as lipid membranes
[90].
Several drugs were found to in£uence the bilayer
to HII phase transition in model, as well as biolog-
ical membranes. CPZ [91,92], tetracaine (TTC) [92],
and dibucaine (DBC) [91^93], as well as the anti-
cancer drugs adriamycin [94] and doxorubicin [95]
have been found to favor [93,95] or to prevent
[91,92,94] the bilayer to HII phase transition, de-
pending on the lipid composition.
Drugs, similarly to classical surfactants, also in-
duce exo- and/or endovesiculation from RBC ([96],
Malheiros, Brito, Brites and Meirelles, submitted).
Sphero-echinocytogenic amphiphiles induce exovesi-
culation, whereas stomatocytogenic amphiphiles in-
duce endovesiculation. Since vesiculation implies a
fusion event, again the likelihood of non-bilayer
phase formation has to be considered. The involve-
ment of speci¢c states of lipid asymmetry was also
suggested. Vesicular fragments from RBC mem-
branes treated with amphiphilic drugs at concentra-
tions lower than lytic were extracted by hygroscopic
desorption ¢ltration [97]. This phenomenon was sug-
gested to be due to amphipath-induced gross redis-
tribution of components in the plane of the mem-
brane.
One of the most studied amphipathic drugs, CPZ,
was also shown, by freeze fracture electron micros-
copy, to induce intramembrane particles clustering
and formation of round patches nearly devoid of
these particles [98], to inhibit RBC cholinesterase
by a micellar mechanism [99], and to solubilize
RBC [100] and synaptic membrane proteins [101].
Yasuhara et al. [102] suggested that the study of
membrane e¡ects of drugs on erythrocytes could be
useful for screening for hepatotoxicity in vitro.
Although it is widely believed that drugs seem to
cause cell lysis by a mechanism very similar to that
described for classical detergents, not many studies
have been performed with the scope of demonstrat-
ing this sequence of events. Malheiros et al. studied
the interaction of the antipsychotic drug TFP and
the LA DBC with RBC. Both TFP and DBC display
the biphasic e¡ect [103,104]. The authors found that
at pH 7.4, when the drug is mainly positively
charged, TFP micelles are formed. Above its cmc
(Table 1), TFP induced membrane disruption and
release of drug-bound membrane lipids into the me-
dium (Malheiros, Brito, Brites and Meirelles, submit-
ted). In contrast, for DBC, drug binding increased
until membrane saturation was reached, but hemol-
ysis occurred at an anesthetic concentration below
the cmc.
Disruption and solubilizing e¡ects of drugs upon
model membranes have been reported. It has been
shown that the cationic form of the LA TTC forms
micelles [12,36] that destroy the bilayer structure of
egg phosphatidylcholine (PC) vesicles, giving rise to
mixed TTC^PC micelles, as seen by light scattering
[36] and spin probes EPR spectra [12]. Dilution to
concentrations below the anesthetic’s cmc restored
the bilayer structure. These observations are in line
with reported toxic e¡ects of the LA [105,106].
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CPZ was found to solubilize lipid membranes (via
MM formation) [107,108] and to promote endovesi-
culation [109]. Endovesiculation was also promoted
by DBC and by sa¢ngol [109]. Liposome solubiliza-
tion was triggered by the weakly ionizable drugs pro-
pranolol [110] and cefotaxime [111]. The non-steroid
antiin£ammatory drugs diclofenac [112] and ibupro-
fen [113] converted liposomal dispersions into drug-
containing MM. Piracetam, a non-ionizable, non-
metabolized drug that improves erythrocyte deform-
ability, caused changes in the 31P NMR spectra of
PC membranes that were ascribed to an isotropic
phase due to mobile drug^phospholipid complexes
[114]. Garcia and Perillo [115] found that £unitraze-
pam caused a decrease in aggregation number and
stability, and an increase in the curvature of dipal-
mitoyl PC vesicles. Negative staining electron mi-
croscopy showed a decrease of 2^3 times of the
mean vesicle diameter.
3.2. AmB^membrane interactions
The binding of AmB to biological and model
membranes has been studied for a long time. Its
mechanism of action is thought to involve interaction
with sterols, leading to pore formation and increased
permeability, and, ultimately, to membrane disrup-
tion and cell lysis (however, see [116]). The AmB
pore was proposed to consist of antibiotic molecules
intercalated with sterol molecules [117,118]. Single
channel measurements suggested a dynamic nature
for the pore [119]. The higher a⁄nity for fungal er-
gosterol over mammalian cholesterol has been in-
voked as the explanation for the antibiotic’s selectiv-
ity for the fungal membrane. AmB is able to lyse
RBC and to induce lipid £ip-£op [85]. In model sys-
tems, it can cause a very fast loss of the inner con-
tents of egg PC^cholesterol vesicles [120], possibly
through a detergent-like e¡ect [121].
Since the equilibrium between monomers and ag-
gregates appears to play a key role in drug activity,
in more recent years, work has aimed at understand-
ing the membrane e¡ects of the antibiotic in terms of
its aggregation state and of the di¡erences in its af-
¢nities for cholesterol and ergosterol as a function of
the aggregation state. Bolard et al. [122] found that
the binding of the antibiotic to membranes in mono-
meric or in aggregated form depends on the lipid
composition, and toxic e¡ects were ascribed to the
aggregated state. Thus, while aggregated AmB is ca-
pable of lysing both RBC (cholesterol-containing
membranes) and fungi (ergosterol-containing mem-
branes), the monomer is active only against the lat-
ter. We will return to this topic, when discussing the
use of surfactants for drug delivery (Section 6.3).
The e¡ect of AmB aggregation state on its inter-
action with ergosterol- and cholesterol-containing
phospholipid monolayers was investigated at antibi-
otic concentrations where it existed either as mono-
mers, or as micelles, or as aggregates of micelles
[123]. While the monomer interacted only with ergos-
terol-containing monolayers, the micellar form inter-
acted with monolayers containing either sterol, in a
di¡erential manner. It was proposed that the activity
of AmB is most likely related to its micellar form.
The large micellar aggregates were able to extract
cholesterol from the monolayer, and were suggested
to be the antibiotic’s toxic form.
DSC studies not only corroborated the previously
observed di¡erences between cholesterol- and ergos-
terol-containing membranes [124] but also indicated
that AmB is able to interact with pure dipalmitoyl
PC, as previously seen by CD spectroscopy [125] and
by permeability enhancement [120]. Phospholipid
complexation by AmB in chloroform solution was
also demonstrated by means of CD and NMR [126].
Studies with sterols, in aqueous or mixed aqueous^
organic solvents, paralleled the results obtained with
model membranes or in toxicity studies, indicating
that AmB interacts more favorably with ergosterol
than with cholesterol [127^129].
3.3. Antimicrobial peptides
Many peptides possess pharmacological activity. A
great number are active against bacteria, fungi, vi-
ruses, and, sometimes, tumors. They are synthesized
by all forms of life, from bacteria to vertebrates,
including mammals, and also by plants (for reviews
see [27,130]). Indeed, at present, the notion exists
that a parallel non-immune defense system exists
based on the ability of organisms to synthesize pep-
tide antibiotics. The research in this ¢eld is very in-
tense, especially in view of the need of new drugs
because of bacterial resistance to the presently used
antibiotics. This intense activity can be appreciated
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by the publication of two recent review issues (Bio-
polymers, Volume 47, number 6, 1998, and Biochim.
Biophys. Acta, Volume 1462, number 1, 1999), in
addition to some excellent review articles on this
topic [27,130^136].
Various antibiotic peptides possess D- (gramicidin
A) or unusual amino acids (alamethicin). Some are
bound to a fatty acid chain at the N-terminal; in
some cases the acyl chain carries a hydroxyl group
that is esteri¢ed by the peptide C-terminal, forming a
cycle (polymyxin B). Interestingly, some peptides
carry a great number of residues of the same amino
acid (histatin, from human saliva, rich in histidine).
Most antimicrobial peptides are amphipathic, highly
positively charged molecules. This has served as the
basis for the contention that their target site and
their selectivity with respect to bacteria (and tumor
cells) is the cell membrane [27,130], since in these
systems negatively charged phospholipids are present
in the outer monolayer to a larger extent than in
mammalian host cells (however, see [137]). The fact
that all-D amino acid-containing peptides retain es-
sentially the same activity as their native counter-
parts has been taken as an indication for the absence
of speci¢c membrane receptors for these peptides
[138].
From the conformational point of view, they can
organize themselves as linear (magainin, pardaxin,
cecropin, dermaseptin) or cyclic (alamethicin) K-heli-
ces, or L-sheets. L-Sheet-forming peptides are cy-
clized by one (brevinin-1) or more (protegrin I, ta-
chyplesin I, L-defensin-1) disul¢de bonds or by
lactone formation (gramicidin S, tyrocidin) [130].
The spatial organization of gramicidin S is such
that, while the hydrophobic residues are on one
side of the backbone, the polar and ionic residues
point in the other direction [139]. The extensively
studied antibiotic gramicidin A forms a L-helix
[140]. In general, the peptides have a random con-
formation in dilute aqueous solution and acquire sec-
ondary structure upon binding to membranes (never-
theless, see below).
Peptide antibiotics act by increasing membrane
permeability. The molecular mechanism(s) by which
these peptides increase membrane permeability to
ions is the subject of an ongoing discussion. Grami-
cidin A and alamethicin ion channels have been ex-
tensively studied. The channel formed by gramicidin
A L-helix allows water and ion passage [140]. It is
widely accepted that alamethicin acts according to
the ‘barrel-stave’ model (see below).
Several models have been proposed or shown to
operate for linear K-helical peptides. The ‘barrel-
stave model’ (Fig. 3B) consists of a bundle of peptide
molecules inserted in the bilayer in an amphipathic
K-helical conformation with their axes perpendicular
to the surface and their polar and charged amino
acid residues lining the interior of an aqueous pore.
Nevertheless, while this model has been adequate for
certain peptides (alamethicin, pardaxin), it clearly is
not suitable for others (magainin, dermaseptin).
Moreover, some peptides were found to be aligned
with the helix axis parallel to the bilayer normal
[135], leading to the proposal of several mechanisms
that take this feature into account. One of these, the
‘carpet model’ [132], is depicted in Fig. 3A. Accord-
ing to this model, the peptides initially bind to the
membrane surface in a carpet-like manner. Mem-
brane permeation would occur at high peptide con-
centration and disruption would take place when the
whole surface is covered by a monolayer of peptides.
Other models have been proposed whose initial steps
imply peptide binding to the membrane surface: the
toroidal model, by Matsuzaki [133], the wormhole
model, by Huang [141], the in-plane di¡usion model,
by Bechinger [135]. It has been pointed out that all
models have features in common [134,135]. They all
imply a detergent-like e¡ect, with peptide^lipid par-
ticles exiting the membrane.
Experimentally, antimicrobial peptides have been
shown to aggregate in the membrane [142,143], as
well as in aqueous [142,144^146] or aqueous^organic
phase [147]. As for non-peptide drugs (see Section
3.2), hexagonal phase formation (gramicidin A) [84]
and induction of lipid £ip-£op (gramicidin A [86] and
magainin [133]) have been observed. Alamethicin
[148] and gramicidin S [149] were shown to induce
cubic phase formation and the strongly lytic peptide
polymyxin B was seen to cause lipid interdigitation
[150]. Gramicidin S was reported to stimulate the
release of phospholipids from RBC and shape
changes (spiculation) were seen to occur prior to
the release of membrane components [151]. It was
proposed that the peptide molecules accumulated in
the outer half of the bilayer, causing crenation, ren-
dering the membrane structure unstable, with a con-
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sequent release of membrane components. The pep-
tide’s mechanism of action was compared to that of
classical surfactants. The detergent-like e¡ect of pep-
tide antibiotics has been widely documented
[132,135]. In fact, some cannot be used for patients
because of their membrane-disrupting e¡ects.
3.4. Measurement of binding constants and partition
coe⁄cients
The analysis of the e¡ects of drugs upon mem-
branes requires the knowledge of the actual amount
of bound drug. The binding of solutes to aggregated
systems has been analyzed in terms of either binding
or partitioning formalisms.
Kb, the binding constant, is given by:
Kb  SMSM 1
where [S] and [SM] are the concentrations of free and
bound solute, respectively, and [M] is the concentra-
tion of the aggregate-forming compound.




Fig. 3. Possible mechanisms for peptide^membrane interaction. (A) The carpet-like mechanism, whereby peptide molecules line up on
the membrane surface until a critical concentration is reached and a detergent-like e¡ect takes place. At this stage, peptide and mem-
brane components form aggregates that leave the membrane, causing disruption. (B) The barrel-stave mechanism, whereby a peptide
bundle spans the lipid bilayer giving rise to pores that promote increased permeability and, eventually, membrane lysis, by a colloid
osmotic mechanism. It should be noted that at high enough concentration, aggregation in the membrane has been found also in the
case of peptides that function through the pore mechanism, also leading to membrane disruption (see text). Reproduced, by permis-
sion, from [132].
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where n corresponds to the number of moles of sol-
ute, V to volume, and the subscripts m and w to the
membrane (or micellar) and water phases, respec-
tively.
The Kb formalism implies that the water solubility
is not a limiting factor and that saturation is reached
due to the existence of saturable binding sites, yield-
ing a hyperbolic binding isotherm. The partition co-
e⁄cient formalism coincides with the linear part of
the binding isotherm. In this region, the partition
coe⁄cient and Kb are related by Kb = P.V· , where V·
represents the lipid partial molar volume [152].
Nevertheless, a large number of drugs have limited
water solubility, which determines their binding to an
aggregate, i.e. transfer to the aggregate ceases when
the aqueous solubility is reached, and the aqueous
phase becomes saturated (see below).
When working with biological or model mem-
branes, the most common procedure to determine
P is centrifugation and measurement of the solute
fraction remaining in the aqueous phase. This proce-
dure has disadvantages, such as the need to separate
both phases, the centrifugation time (and eventual
chemical reactions taking place during this time),
and the risk of some membrane remaining in the
aqueous phase, and/or some poorly soluble solute
co-sedimenting without actual partitioning [153].
Our laboratory has been engaged in the develop-
ment of methodologies to determine partition coe⁄-
cients without the need of phase separation by mak-
ing use of spectroscopic techniques such as EPR,
NMR, £uorescence. The basic principle consists in
measuring an e¡ect proportional to the amount of
bound drug. A set of equations can be derived for
the calculation of P [154]. A comparison between
P values obtained from £uorescence, spin labeling
and centrifugation data showed good agreement
[154^156].
Another method [155] is based on the knowledge
of the aqueous solubility of the partitioning com-
pound and on the assumption of the following equi-
librium:
Solid1Solute in solution1Membrane-bound solute
A solute distributes between water and membrane
until its water solubility (Sw, saturation) is reached.
When this happens, no more solute will partition
into the membrane, further addition leading to pre-
cipitation of the solid. At this point, a solute-depen-
dent membrane property will reach a maximum.
Since nw is known (from Sw), so is nm (nm =
ntotal3nw), allowing the calculation of P (Eq. 2).
P values for a series of LA determined by this pro-
cedure, using £uorescence and EPR measurements,
were in very good agreement with those obtained
by centrifugation [155].
Fluorescence measurements have been employed
to determine binding constants of several drugs to
membranes or micelles [157^161].
3.5. E¡ect of water structure on binding of drugs to
membranes and micelles
Ions from the Hofmeister series and agents such as
urea are known to a¡ect the solubility of relatively
non-polar compounds in water, as well as their dis-
tribution between water and organic solvents (for a
review, see [162] and references therein). This is
mainly due to the e¡ect of the additives on water
structure. Kosmotropes (sulfate, phosphate, chloride)
increase water order and decrease solute solubility,
while chaotropes (bromide, thiocyanate, perchlorate)
do the opposite. Ions from the Hofmeister series alter
properties of micelles such as the cmc and the aggre-
gation number In addition, chaotropic anions bind
to lipid membranes with high a⁄nity [163].
We have examined the e¡ect of anions of the Hof-
meister series and urea, on the partitioning of
charged and uncharged TTC into zwitterionic mi-
celles [161] and phospholipid bilayers (Sakabe, Ca-
sallanovo, Teixeira and Schreier, in preparation).
The binding of both forms was a¡ected, varying in
the order: ClO34 6SCN
36urea6 bu¡er6Cl36
SO234 . The ions also caused changes in micellar pack-
ing and size. The results were analyzed in terms of
the e¡ects on water structure, ion binding, and
changes in micellar organization, with prevalence of
the former.
4. E¡ects of aggregation on physicochemical
properties of drugs
Amphiphile aggregation gives rise to regions of
di¡erent physicochemical properties. Thus, while
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the hydrophobic core provides an environment of
very low polarity, the head group region consists of
a shell with high charge concentration, in the case of
ionic surfactants, or, at least, of higher polarity, in
the case of non-ionic surfactants. As a result, the
incorporation of an amphiphilic drug into an aggre-
gate, either upon self-association or by intercalation
into other organized assemblies (bilayers, emulsions,
or micelles) will a¡ect its physicochemical properties,
e.g. the degree of ionization, reaction rates, and,
eventually, reaction mechanisms.
4.1. Charge e¡ects: pK shifts
In 1976, McLaughlin and Harary published an
analysis of the binding of charged species to lipid
bilayers based on the Guy^Chapman theory [164].
This work was extended to ionizable compounds by
Lee [157], who showed that whenever the binding
constants for the charged and uncharged forms are
di¡erent, this will imply a pK shift. The binding con-
stant for the charged species was described as con-
sisting of an intrinsic value plus the contribution of
charge e¡ects due to the ligand itself, of the ions in
solution, and the charge on the lipid head group
[157,165,166].
Several de¢nitions of pK for compounds partition-
ing between membrane and aqueous phase have been
presented [167]. We have de¢ned an apparent pK,
pKapp, that corresponds to the pH in the aqueous
phase where the sum (charged species in the mem-
brane+charged species in the aqueous phase) equals
the sum (uncharged species in the membrane+un-
charged species in the aqueous phase) [168]. It should
be noticed that pKapp will depend on membrane con-
centration. Therefore, if one of the forms, charged or
uncharged, of a drug is the pharmacologically active
species, its concentration will vary with membrane
concentration. The membrane pK, pKm, is the pH
in the aqueous phase at which the concentrations
of the charged and uncharged species, in the mem-
brane, are equal. pKm does not depend on membrane
concentration. The pK shift, vpK ( = pKw3pKm,
where pKw is the pK in water), is a consequence of
the di¡erent binding constants for the charged and
uncharged species. This can be visualized in Scheme
1, where P and P0 are the partition coe⁄cients for
the charged and uncharged species, respectively.
pKapp and pKm are related to experimentally de-
termined partition coe⁄cients [166]:
pKapp  pKw  logfPWVm  Vw=P0WVm  Vwg
3
and
pKm  pKw  logP=P0 4
vpK can be positive, zero, or negative, depending
on solute and membrane surface charge [166]. Gar-
cia-Soto and Fernandez [169] have shown that, while
vpK for TTC increases in the presence of negatively
charged micelles, it decreases in the presence of non-
ionic micelles, and decreases to a larger extent when
the micelles are positively charged. This is due to the
fact that in the ¢rst case PchargedsPuncharged, while in
the two latter systems the opposite is true. Similar
results were found by Strichartz and coworkers [170],
who determined pK shifts for a series of LA in mi-
celles of variable surface charge.
pK shifts were found for a series of drugs upon
binding to micelles or bilayers [104,158,165,168,171^
174].
4.2. E¡ects of drug binding on reaction kinetics
The use of surfactants in pharmaceutical formula-
tions is quite common not only as a tool to solubilize
slightly soluble drugs but also to protect them from
degradation. The stability of the drug in micelles may
be altered favorably or unfavorably.
Oliveira and Chaimovich [175] have reviewed the
e¡ects of detergents and other amphiphiles on both
the rate and the mechanism of reactions. The authors
also provided a quantitative analysis of the micellar
e¡ects on the stability of L-lactam antibiotics in the
presence of micelles [176,177] and emulsions [178],
Scheme 1.
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emphasizing the e¡ects of the aggregates on the rate
and/or mechanism of the reaction.
Scheme 2 [179] presents the possible events for
reactions occurring when a substrate partitions be-
tween water and a second phase.
Only a situation where there are no charge e¡ects
will be considered. The observed pseudo-¢rst order
rate constant, k8, is given by the equation:
k8  kmM  kw1 kbM 5
where km and kw are the pseudo-¢rst order rate con-
stants in the aggregate and in water, respectively, Kb
is the binding constant, and [M] is the concentration
of the aggregate-forming compound(s) [179].
km and kw were determined for the alkaline hydro-
lysis of a spin-labeled benzoate [180] and of several
TTC analogues in the presence of liposomes ([152],
and Bianconi, Amaral and Schreier, in preparation).
The determination of Kb at variable temperature
yielded the thermodynamic parameters of binding:
vG, vH, and vS. The data (vHs 0, vSs 0) showed
that the binding was in agreement with the classical
hydrophobic e¡ect. Although ordering of the solute
in the membrane environment should make a nega-
tive contribution, the loss of water of hydration must
play a predominant role, determining the positive
value of vS. Similar results were found for a homol-
ogous series of alcohols [181]. The TTC analogues
were able to self-associate. In the aggregated form,
the compounds were hydrolyzed at a slower rate
[182].
Since aminoester anesthetics are cleared from the
circulation upon hydrolysis by extracellular, non-spe-
ci¢c esterases, these kinetic studies provide a ration-
ale for the higher e⁄ciency and toxicity of the more
hydrophobic anesthetics [183].
Changes were observed in the kinetics and/or
mechanism of reaction upon self-aggregation or in-
corporation into micelles, bilayers, or microemul-
sions of methylprednisolone 21-hemiesters [184], LA
[185,186], carbaryl [187], 1,4-benzodiazepines [188],
acetylsalicylic acid [189], and L-lactam antibiotics
[190].
5. Phospholipidosis: a pathology induced by ionizable
cationic amphiphilic drugs (CADs)
Phospholipidosis is a striking example of a patho-
logical condition resulting from the interaction of
amphiphilic drugs with membranes. Lipidosis-induc-
ing CADs have a charged nitrogen group in close
proximity to a hydrophobic moiety (an aromatic or
aliphatic ring structure). Drugs belonging to di¡erent
classes (antidepressant, anorexic, inhibitors of choles-
terol synthesis, antihistaminic, antimalarial, antiin-
£ammatory, antibacterial, antipsychotic, antiarrhyth-
mic, antiestrogenic, and inhibitors of serotonin
uptake) can induce lipidosis [191]. CADs cause phos-
pholipid storage disorders; they are called lysosomo-
tropic drugs because of their a⁄nity for the acidic
interior of lysosomes. It is believed that the un-
charged form of the molecules crosses the lysosomal
membrane to ¢nd a low pH milieu, favoring its rapid
protonation. Phospholipids would bind to this form,
taking it out of equilibrium; if enough drug enters
the lysosome, the increase in pH could a¡ect the
activity of lysosomal enzymes [192].
Lipidosis is characterized by the appearance of
lipid lamellar bodies or, less commonly, crystalloid
inclusion bodies (identi¢ed with HII phase), inside
the cell [192,193]. These structures originate from
lysosomes. Their lipid composition is di¡erent from
that in Niemann^Pick or Tay^Sachs diseases, and is
characterized by an enhanced concentration of polar
lipids. Acidic phospholipids, such as phosphatidyl-
inositol and bis(monoacylglycerol)phosphate accu-
mulate to a greater extent than zwitterionic phospho-
lipids in hepatic and renal tissues [194,195], while PC
increases mainly in the lung [196].
Theories for the occurrence of lipidosis include in-
hibition of lipid catabolism by drug^substrate com-
plexes or by increased pH inside the lysosome, with
inhibition of enzymes involved in phospholipid ca-
tabolism [195,197] and increased phospholipid bio-
synthesis [191,192,194]. It is also proposed that the
drugs interfere with phospholipid metabolism by di-
rectly binding to enzymes. The inhibitory e¡ect of
Scheme 2.
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CADs upon phospholipid catabolizing enzymes was
described for a series of drugs [195,198]. When the
drug is rapidly metabolized in vivo, as is the case for
several L-blockers [199] and LA, lipidosis does not
occur, since the drugs are not accumulated inside the
organelle.
Lipidosis can be reverted by stopping drug admin-
istration. Otherwise, the inclusion bodies appear to
disintegrate with time into membranous and granular
debris [192]. Pathological implications include cor-
neal opacity [200], decreased glomerular ¢ltration
[201], acute renal failure [202], pulmonary pneumo-
cystis [197] and ¢brosis, increased hepatic density,
and depressed immune response [191].
6. Solubilization and delivery of amphiphilic and
hydrophobic drugs by synthetic and biological
surfactants
Since many drugs are amphiphilic or hydrophobic,
several problems arise with respect to their formula-
tion, solubilization in body £uids, and interaction
with barrier membranes in the organism, to reach
their ¢nal targets. The e¡ects of micellar solubiliza-
tion on the solubility and absorption of non-polar
solutes are quite well documented. A large number
of systems, making use of micelles and other organ-
ized lipid assemblies, are presently under study for
the purpose of drug delivery.
We will focus on work concerning the use of sur-
factants, in the form of micelles, as vehicles for spar-
ingly water-soluble drugs. Solubilization is a conse-
quence of the presence of hydrophobic domains in
the surfactant aggregates acting as microenviron-
ments for hydrophobic solubilizates. We will present
studies of drug^surfactant interactions from a phys-
icochemical standpoint, as well as applied aspects,
such as drug bioavailability, absorption, and the
multiple surfactant e¡ects, including toxic ones. In
some cases, solubilization has been found to be or-
ders of magnitude larger than in the absence of sur-
factants.
Both synthetic and biological surfactants (mostly
bile salts) have been employed. Although non-ionic
surfactants are more physiologically tolerable than
ionic ones, they usually have a lower solubilizing
capacity. The polar region of many non-ionic surfac-
tants consists of polyoxyethylene (POE) or polyethyl-
eneglycol (PEG). Their micelles can be considered as
formed by several microdomains: hydrocarbon,
POE, POE/water. A cross section of a POE surfac-
tant micelle thus o¡ers a range of solubilization re-
gions of di¡erent polarities.
6.1. Physicochemical aspects of solubilization
The thermodynamics of solubilization of a series
of steroids (hydrocortisone, dexamethasone, testos-
terone, and progesterone) by long chain POE surfac-
tants was investigated [203]. The partition coe⁄cients
increased with decreasing steroid polarity and de-
creased with temperature. The standard free energy
change of solubilization, vG0s decreased with decreas-
ing steroid polarity, but was essentially temperature-
independent. The change in enthalpy, vH0s was neg-
ative indicating that solubilization was energetically
favored. vH0s became more positive as the steroid
polarity decreased. Hydrocortisone and dexametha-
sone (more polar) were solubilized with a negative
change in entropy, while testosterone and progester-
one (less polar) provided a positive change. Two op-
posing factors were proposed to be involved: inser-
tion of solubilized molecules in the micelles (a more
ordered system) restricts the molecular motion and
contributes to a decrease in entropy. On the other
hand, when a relatively non-polar molecule migrates
from the aqueous to the micellar phase, the loss of
water of hydration causes a positive entropy change.
For the more polar steroids, the negative contribu-
tion predominates, since, by being incorporated in
the outer, more hydrated, POE shell, they very likely
do not lose their hydration water.
The solubility of a series of barbituric acids in-
creased with surfactant concentration and with tem-
perature [204]. The apparent distribution coe⁄cient
decreased with temperature, indicating that the sol-
ubility in water increased faster than in the micelles.
vG0s and vH
0
s were negative for the whole series of 13
barbituric acids, while vS0s was negative, or zero, for
nine of them. It was concluded that most of the
drugs are absorbed in the micellar surface region.
The enthalpy/entropy compensation phenomenon
whereby vG0s remains essentially constant with in-
creasing temperature at the expense of compensatory
changes in vH0s and vS
0
s , was also discussed. Linear
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correlations were found for enthalpy/entropy com-
pensation, as well as between vG0s and the molecular
surface area of the compounds.
In various studies linear correlations were estab-
lished between the micellar/water distribution coe⁄-
cients and partition coe⁄cients in octanol/water
(Po=w) for a series of poorly water-soluble drugs
[205,206], pointing at the role of solute lipophilicity
in solubilization.
A model was developed to estimate the increase of
drug solubility as a function of micelle concentration
[207]. An equation correlating the solubilization ratio
(SR = SCbs/SCaq, where SCbs and SCaq are, respec-
tively, the solubilization capacities in BS and in
water) with log Po=w was established for a collection
of steroids and found to apply, with minor modi¢-
cation, to a collection of non-steroidal, highly lipo-
philic compounds. The results indicated that the in-
crease in drug solubility as a function of BS
concentration can generally be predicted simply on
the basis of Po=w and the compound’s aqueous sol-
ubility.
When dealing with ionizable compounds, pH ef-
fects have to be taken into account. The solubiliza-
tion of a series of substituted benzoic acids in non-
ionic micelles was pH-dependent, increasing with de-
creasing pH, i.e. when the solutes became uncharged
[208]. The partition coe⁄cient of the unionized spe-
cies increased with increasing lipophilicity of the ben-
zoic acid derivative.
6.2. Mechanisms for surfactant improvement of drug
absorption: solubilization, wetting, and membrane
e¡ects
The analysis of the mechanism of drug^surfactant
interaction involves a complex ensemble of possibil-
ities. Besides e¡ective solubilization, phenomena like
wetting play a role in drug dissolution. The mecha-
nism of wetting implies that dissolution is favored by
a reduction of the interfacial tension between the
drug and the medium by the surfactant. Bakatselou
and coworkers [209] studied the solubilization and
wetting e¡ects of a BS on the dissolution of steroids.
For all compounds, wetting e¡ects predominated
over solubilization at low (pre-micellar) BS concen-
tration, representative of the fasted state. For the
more polar compounds, this trend continued at high-
er BS concentrations, typical of the fed state. In-
stead, for the more lipophilic compounds, solubiliza-
tion was the predominant mechanism under the
latter conditions. When comparing the dissolution
of two non-steroidal antiin£ammatory drugs by BS,
it was found that, while solubilization was the pre-
vailing mechanism for one drug, wetting was the
dominant process for the other [210].
A large number of studies focus on the bioavail-
ability and absorption of drugs in vivo when admin-
istered with BS. Ho«rter and Dressman [211] have
reviewed the in£uence of physicochemical properties
on the dissolution of drugs in the gastrointestinal
(GI) tract. According to the authors, the rate-limiting
step for drug absorption from the GI tract is often
dissolution from the dosage form. Solubility in the
GI contents is determined by aqueous solubility,
crystalline form, drug lipophilicity, co-ingested food-
stu¡s, pKa in relation to the GI pH pro¢le, and sol-
ubilization by native surfactants. In the small intes-
tine, micellar solubilization of the drug can occur
when the amphiphilic bile components (BS, PC,
and monoolein) reach concentrations higher than
their cmc.
The results obtained in studies with BS or other
largely employed surfactants are variable. BS re-
duced the bioavailability of the drug atenolol [212]
and BS/oleic acid MM [213] did not have a pro-
nounced bene¢cial e¡ect on the transfer of lipophilic
drugs in the rat small intestine. Nevertheless, it is
remarked that in vivo these micelles can promote
the overall process of absorption of poorly water-
soluble drugs by enhancing their dissolution rate,
which in many cases is the rate-limiting step [213].
Micelle solubilization of the antibiotic cefadroxil by
sodium dodecyl sulfate (SDS), a surfactant widely
used in drug formulations, was minimal [214]. The
great increase in the drug’s apparent absorption rate
in the rat colon was ascribed to a direct e¡ect of the
surfactant on the absorbent membrane.
In vitro studies were conducted with gem¢brosil
[215], a lipid-lowering agent, in model systems ap-
proximating the conditions of the upper GI tract,
to identify drug physicochemical properties a¡ected
by endogenous and dietary lipids. When increasing
amounts of bile components were added, the drug’s
solubility increased with respect to that in BS alone.
Under conditions mimicking the fed state, the solu-
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bility was improved when compared to the fasted
state.
The fact that food intake can a¡ect the bioavail-
ability of poorly water-soluble drugs led to the inves-
tigation of the ability of freeze-dried drug milk for-
mulations [216] and milk fat globule membrane [217]
to bind several compounds and to in£uence their
intestinal absorption. It was concluded that these
systems have a potential for in vivo drug delivery.
That the surface activity of the drug itself can play
a role in drug absorption was demonstrated by an
increase in colonic permeability for the inhibitor of
cholesterol biosynthesis, £uvastatin, with increasing
drug concentration [218]. The e¡ect was ascribed to
a drug-promoted decrease of the surface tension at
the membrane surface.
Nasal absorption is often employed for systemic
delivery of protein and peptide drugs. Although
small peptides can be readily absorbed through the
nasal mucosa, larger molecules exhibit little or no
bioavailability, and improvement in their absorption
requires permeation enhancers. Among a number of
surfactants, BS have been used to enhance the nasal
or oral absorption, in particular of peptide drugs
such as insulin [219], calcitonin [220], and growth
hormone [221]. The data corroborated the hypothesis
that BS act as absorption adjuvants by producing a
high juxtamembrane concentration of insulin mono-
mers via solubilization in MM, and by forming re-
verse micelles within nasal membranes through
which the drug monomers can di¡use through polar
channels from the nares to into the blood stream
[219]. BS not only increased the oral absorption of
human calcitonin, but also inhibited its degradation
[220]. The pulsatile absorption kinetics observed after
intranasal delivery of growth hormone [221] re-
sembled its endogenous secretory pattern more
closely than upon subcutaneous administration.
Several studies have focused on model and biolog-
ical membrane-damaging e¡ects by surfactants used
in drug formulations [222^226]. Besides increasing
drug solubility and dissolution rate, BS also increase
absorption by altering the permeability of biological
membranes. Indeed, elevated levels of BS and lysoPC
in the stomach, as a result of bile re£ux, have been
implicated in gastric ulceration [227]. The com-
pounds also caused the breakdown of mucus struc-
ture and were toxic to membranes. Low BS concen-
trations caused pronounced changes in the
appearance of the mucosal surface [228] and acceler-
ated the release of phospholipids and protein from
the membrane [229]. A surfactant-induced increase in
the permeability across various epithelia was sug-
gested to be due to the concentration-dependent sol-
ubilization of cell membranes [230].
Although BS and lysoPC are apparently toxic to
the gastric mucosa, as well as to in vitro prepara-
tions, no extensive destruction of the intestinal mu-
cosa occurs. Normal human gall bladder bile con-
tains about 85% water, 7.6% BS, 3% PC, 0.5%
cholesterol and 3.5^4% other components [231].
Thus, a study was performed to verify whether PC,
the major phospholipid in bile, would reduce the
toxicity of BS and lysophospholipids to biological
membranes by combining with them to form MM
[222]. Indeed, PC incorporation into the aqueous
medium reduced the toxicity caused by both BS
and lysoPC. In addition, PC provided protection
against membrane damage by SDS. MM formation
was proposed to account for the protective e¡ect and
it was suggested that they could be convenient drug
carriers.
6.3. Mixed micelles as solubilizing agents
MM have been extensively used as drug solubiliz-
ing agents, as well as delivery systems. Their toxicity
or therapeutic index (TI) have been compared to
those of other lipid carriers. Mixtures of sodium
cholate and PC in water can achieve di¡erent organ-
izational states depending on the proportion of the
components: lamellar, cubical, hexagonal, micellar
[231]. The extent of diazepam solubilization followed
the order: lamellars cubicals hexagonalsmicellar.
Phospholipid^detergent MM were also used to solu-
bilize teniposide [232], taxol [233], hydrocortisone
[234], gem¢brosil [215], retinoids [235], several ben-
zodiazepines [236], and AmB (see below). MM were
shown to convert to vesicles upon dilution, while
keeping the water insoluble drug [232,233]. In most
cases, MM were less toxic than single-component
micelles of the corresponding surfactant. It was
also seen that, while wetting e¡ects predominate in
the BS-only system, solubilization is the most impor-
tant mechanism in MM for the dissolution of hydro-
cortisone. MM not only improved the solubility of
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tetrazepam, but also increased the drug stability
[237].
MM of variable composition have been investi-
gated with respect to their ability to decrease AmB’s
toxicity and/or improve its TI.
The TI of AmB in phospholipid^BS MM was
compared to that of the commonly used formulation
Fungizone (AmB-DOC, 1:2) [238]. While K leakage
from RBC and cultured L cells treated with Fungi-
zone was almost complete, MM had no e¡ect. In
contrast, both preparations were e¡ective against
fungal cells. Absorption and CD spectra showed
that, while the antibiotic dissociated slowly in the
monomeric form from the MM, it dissociated rapidly
as a mixture of monomers and self-aggregates from
Fungizone. The results corroborated the hypothesis
that aggregated AmB is toxic to host cells, while the
monomeric antibiotic can a¡ect the viability of the
infecting fungi. We have also shown that the toxicity
of the antibiotic to RBC decreased, while its e⁄cacy
against fungal cells was retained when it was incor-
porated in a chylomicron-mimetic emulsion [239].
Dangi and coworkers [240] examined the solubility
and GI membrane permeability of AmB in BS-con-
taining MM and found that the drug’s absorption
rate was enhanced over 20-fold with respect to that
of simple micellar systems.
MM of AmB and lauryl sucrose were examined,
both with respect to their ability to bind to mem-
brane sterols [241] and their activity and toxicity to
fungal cells and RBC [242]. The data were compared
with results found for AmB-DOC MM. In both
cases, stoichiometries were found where AmB^sur-
factant complexes were formed, destroying the micel-
lar structure. The interaction between AmB and laur-
yl sucrose was stronger than with DOC. It is also
noteworthy that the DOC-AmB MM, where the
antibiotic was in the monomeric form, was less toxic
than Fungizone. At surfactant concentrations where
AmB was monomeric, the preparations inhibited the
toxicity to RBC and cultured mouse ¢broblasts more
than to fungal cells.
Based on the fact that heating AmB solutions
leads to the formation of super-aggregates [59] Petit
and coworkers [243] examined the e¡ect of mild heat-
ing of Fungizone and of an AmB-DOC formulation
on the in vivo therapeutic e⁄cacy in experimental
murine mycoses. An improvement of antifungal ac-
tivity was obtained with the heated formulations due
to their lower toxicity. It was suggested that mild
heating of the already used pharmaceutical prepara-
tion could improve the drug’s TI by reducing its
toxicity to mammalian cells. Heat-induced super-ag-
gregates were formed from AmB, Fungizone, and
Amb-DOC preparations. It was observed that solu-
ble aggregates, capable of interacting with cholester-
ol-containing membranes, were the toxic form of
AmB.
Another colloidal delivery system, consisting of
AmB and cholesteryl sulfate MM (ABCD, AmB col-
loidal dispersion, marketed as Amphocil) has been
investigated [244]. A signi¢cant TI was found in ani-
mal studies, which was ascribed to stabilization of
the MM by strong van der Waals forces. In this
paper, a very interesting discussion about the condi-
tions that favor the formation of large disk-like MM
and about the concept of thermodynamic stability
with regard to these and other colloidal systems is
presented by the author.
AmB incorporated in polymeric micelles (PM) of a
POE block poly(L-benzyl aspartate) copolymer (see
below) yielded a very good loading e⁄ciency, was
non-hemolytic, and was released gradually, indicat-
ing that PM are a convenient system for AmB deliv-
ery [245].
The wealth of work on AmB shows that, although
its DOC formulation (Fungizone) has been in clinical
use for several decades, and some of the newer prep-
arations are also starting to be used with patients,
and in spite of the large amount of work on model
systems, cells, and animal models, the basic physico-
chemical (thermodynamic and kinetic) rules underly-
ing the aggregation behavior of this antibiotic are
still unsolved.
6.4. PM as solubilizing agents
Long circulating carriers are desirable delivery sys-
tems in order to maintain blood levels of drugs, to
achieve speci¢c targeting (e.g. tumor cells), and for
use with contrast agents (e.g. atherosclerosis diagno-
sis) [246]. Liposomes and microspheres are quite
readily scavenged in a non-speci¢c manner by the
reticuloendothelial system (RES) [247].
PM consist of A-B or A-B-A block copolymers,
where A represents hydrophilic and B hydrophobic
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polymeric chains. Such micelles provide increased
water interaction, decreased retention by RES, and
prolonged circulation time in the blood
[246,248,249]. Usually, the hydrophilic portion of
PM consists of POE. POE is a low toxicity biomed-
ical polymer and, when present at interfaces or sur-
faces, has the ability to suppress cellular and protein
adsorption, therefore, it does not bind to blood com-
ponents. PM circulate in blood for long times by
escaping the renal ¢ltration due to their hydrated
outer shell and larger size, relatively to the isolated
polymer chains [247]. In low vascular permeability
tumors, carriers with a smaller size than liposomes
may provide more e⁄cient drug delivery [250].
Pluronic polyols are block copolymers of hydro-
phobic polyoxypropylene (POP) and hydrophilic
POE; their micelles (diameter ca. 50 Aî ) can be e¡ec-
tively placed in the colloidal size range [249]. They
are among the less toxic surface active agents and are
widely used for drug delivery [251^253]. In other
PM, biodegradable compounds such as polypeptide
chains, mainly of Asp [246,254], benzyl-Asp [255] or
Ala [256] form the core of the particles. Also poly-
lactic acid [257] and polyglycolic acid [258] have been
used.
Chung et al. [259] reported the use of PEG-N-iso-
propylacrylamide, a thermo-responsive (intelligent)
block copolymer, expected to induce selective accu-
mulation of anticancer drugs controlled by temper-
ature modulation. Moreover, block copolymers have
extended the use of non-ionic detergents into a new
domain with regard to membrane disrupting activity.
By controlling of the chemical structure of block co-
polymers, tunable membrane-disrupting agents have
been synthesized [260].
7. Hydrotropy
Another approach to improve the solubility of
sparingly water-soluble drugs consists in using the
concept of hydrotropy. Hydrotropes are molecules
that, at reasonably high concentrations, promote sol-
ubilization. Among well-known hydrotropic agents
are urea, ca¡eine and other xanthine derivatives,
tryptophan, certain antihistamines, sodium benzoate,
sodium salicylate, and nicotinamide [261].
Several mechanisms have been proposed to ac-
count for the molecular process of solubilization:
Z^Z complex formation, salting-in, changes in the
nature of the solvent and hydrotrope aggregation
[261]. It is believed that the mechanism varies for
di¡erent systems.
The increase of the aqueous solubility of the cyto-
toxic agent chartreusin in the presence of hydroxy-
benzoates was interpreted as resulting from a plane-
to-plane orientation of the drug and hydrotrope mol-
ecules brought together by electrostatic and hydro-
phobic interaction; solubilization was interpreted in
terms of micellization [262].
Co¡man and Kildsig examined the solubilization
of ribo£avin by nicotinamide and proposed that hy-
drotrope self-association plays a role in the mecha-
nism of solubilization [261]. In contrast, complex for-
mation was proposed to be the mechanism for the
solubility enhancement of anticancer nucleoside ana-
logues [263] and of a bisnaphthalimide tumoricidal
agent, DMP 840 [264], by nicotinamide. Improved
solubilization of rhodium carboxylate adducts, a
new class of sparingly soluble cytotoxic compounds,
was achieved by complexation with isonicotinic acid
[265]. Complexation was also invoked as the mecha-
nism of solubility enhancement of thiocetazone, a
drug used in the treatment of tuberculosis, by isonia-
zid [266].
The behavior of hydrotropes, lower alkanoates,
alkyl sulfates and alkylbenzene sulfonates, was com-
pared to that of their longer analogues, known to
form micelles [267]. The hydrotropes were found to
self-associate and form non-covalent assemblies of
lowered polarity beyond a certain concentration
(minimal hydrotrope concentration). The aggregates
were found to consist of planar or open-layer struc-
tures, instead of more compact, spherical micelles. In
this case, solubilization would occur in the aggregate
lipophilic region.
8. Prodrugs
In order to improve the solubility of a poorly solu-
ble drug, prodrugs, either water-soluble or organized
in a micellar arrangement, can be synthesized and
converted to the active parent compound in vivo.
Micellar prodrugs have additional advantages in
that their micelles solubilize poorly soluble degrada-
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tion products which can otherwise precipitate, and
may act as self-stabilizing due to protection of the
hydrolytically labile prodrug linkage within the mi-
celle interior [268].
Some hemiester derivatives of water insoluble cor-
ticosteroids self-associate in water to form micelles.
This approach was used in the development of mi-
cellar prodrugs of methylprednisolone [268]. Choles-
teryl ester prodrugs of ibuprofen and £ufenamate
were synthesized and solubilized in microemulsions
[269]. Self-association of a prodrug of phenytoin
also caused a decrease in its rate of hydrolysis, as
well as increased solubilization of the parent drug
[270]. Similarly, increased solubilization was achieved
by synthesizing PEG-derived prodrugs of amino
group-containing compounds leading to extended
plasma circulation half-lives and, in the case of anti-
cancer agents, apparent tumor accumulation [271].
9. Surfactants as drugs
In view of their ability to alter the permeability of
cells, surfactants display antibacterial properties by
acting on bacterial cell walls. Long-chain surfactants
containing quaternary ammonium or pyridinium
ions as headgroups have been used as bactericidal
or bacteriostatic agents. Kopecky [272] has reviewed
this topic. More recently, vesicles made of a double-
chain quaternary ammonium ion were also shown to
have bactericidal properties [273].
Trimethyl alkylammonium compounds, with alkyl
chains ranging from two to 16 carbons, display ultra-
long lasting anesthetic activity [274] that increases
with increasing chain length. The C12 derivative pro-
duced almost irreversible (17^20 days) anesthesia.
Neurotoxic e¡ects render these compounds unaccept-
able for clinical use; the authors ascribed these ef-
fects to the detergent nature of the compounds.
10. Concluding remarks
The data presented in this work have focused on
surface active drugs. Studies investigating their self-
association properties were described. As for their
e¡ects upon membranes, the literature presented
demonstrates that, whatever the detailed mechanism
of their membrane activity and whatever the nature
of their self-association, amphiphilic drugs interact
with membranes, exerting a variety of e¡ects, at the
molecular level, from changes in lipid organization to
channel formation, induction of lipid £ip-£op and of
non-bilayer and interdigitated phases. These e¡ects
correlate with cell shape changes, membrane vesicu-
lation, disruption, and, ¢nally, solubilization. The
e¡ects of drugs are analogous to those of classical
detergents. Similarly to the latter, drugs are able to
extract membrane lipids and proteins. Pathological
consequences of the interaction between cationic am-
phiphilic drugs and membranes were discussed.
It was shown that physicochemical properties (de-
gree of ionization, reaction kinetics) are modulated
by the drugs self-association or by their binding to
other lipophilic aggregates.
Another important issue concerning amphiphilic
and hydrophobic drugs is their solubilization. Solu-
bilization by classical surfactants, mixed micelles,
polymeric micelles, and hydrotropes was discussed
from the physicochemical point of view and in terms
of their use as drug carriers and absorption in the
organism. The use of micellar prodrugs and of clas-
sical surfactants as drugs was also reported.
Advances in the understanding of the molecular
mechanisms of amphiphiles self-aggregation, of their
interaction with membranes, and of their solubiliza-
tion by di¡erent surfactants will allow the rational
design of more e¡ective and less toxic therapeutic
agents and delivery systems.
Acknowledgements
This work was supported by research grants from
FAPESP to S.S. and E.P. and by a CNPq research
fellowship to S.S. We thank Professor Yechiel Shai,
from the Weizmann Institute of Science, for provid-
ing Figure 3.
References
[1] J.N. Israelachvili, Intermolecular and Surface Forces, Aca-
demic Press, London, 1986.
[2] W.C. Gri⁄n, J. Soc. Cosmet. Chem. 1 (1949) 311^320.
[3] A. Helenius, K. Simon, Biochim. Biophys. Acta 415 (1975)
29^79.
BBAMEM 77971 10-11-00 Cyaan Magenta Geel Zwart
S. Schreier et al. / Biochimica et Biophysica Acta 1508 (2000) 210^234 229
[4] J. Lasch, Biochim. Biophys. Acta 1241 (1995) 269^292.
[5] J.H. Fendler, Membrane Mimetic Chemistry, Wiley-Inter-
Science, New York, 1982.
[6] C. Tanford, The Hydrophobic E¡ect, John Wiley and Sons,
New York, 1980.
[7] P. Mukerjee, J. Pharm. Sci. 63 (1974) 972^981.
[8] R. Nagarajan, E. Ruckenstein, Langmuir 7 (1991) 2934^
2969.
[9] J.R. Ernandes, H. Chaimovich, S. Schreier, Chem. Phys.
Lipids 18 (1977) 304^315.
[10] S. Schreier, J.R. Ernandes, I.M. Cuccovia, H. Chaimovich,
J. Magn. Reson. 30 (1978) 283^298.
[11] Z. Liang, P. Westlund, G. Wikander, J. Phys. Chem. 99
(1993) 7098^7107.
[12] W.A. Frezzatti Jr., W.R. Toselli, S. Schreier, Biochim. Bio-
phys. Acta 860 (1986) 531^538.
[13] M.C. Carey, D.M. Small, Arch. Intern. Med. 130 (1972)
506^527.
[14] D. Attwood, A.T. Florence, J.M.N. Gillian, J. Pharm. Sci.
63 (1974) 988^993.
[15] D. Attwood, R. Natarajan, J. Pharm. Pharmacol. 33 (1981)
136^140.
[16] A.D. Atherton, B.W. Barry, J. Colloid Interf. Sci. 106 (1985)
479^489.
[17] E. Wajnberg, M. Tabak, P.A. Nussenzveig, C.M. Lopes,
S.R. Louro, Biochim. Biophys. Acta 944 (1988) 185^190.
[18] D. Attwood, V. Mosquera, V. Pe¤rez-Villar, J. Chem. Soc.
Faraday Trans. I 85 (1989) 3011^3017.
[19] D. Attwood, D. Doughty, V. Mosquera, V. Pe¤rez-Villar,
J. Colloid Interf. Sci. 141 (1991) 316^321.
[20] W. Wanbahdi, H. Mwakibete, D.M. Bloor, R. Palepu, E.
Wyn-Jones, J. Phys. Chem. 96 (1992) 918^925.
[21] V. Perez-Villar, M.E. Vazquez-Iglesias, A. Degeyer, J. Phys.
Chem. 97 (1993) 5149^5154.
[22] D. Attwood, V. Mosquera, J.L. Lopez-Fontan, M. Garcia,
F. Sarmiento, J. Colloid Interf. Sci. 184 (1996) 658^662.
[23] D. Attwood, E. Boitard, J.P. Dube's, H. Tachoire, J. Phys.
Chem. 101 (1997) 9586^9592.
[24] M. Perez-Rodrigues, G. Prieto, C. Rega, L.M. Varela, F.
Sarmiento, V. Mosquera, Langmuir 14 (1998) 4422^4426.
[25] D. Attwood, R. Blundell, V. Mosquera, M. Garcia, J. Col-
loid Interf. Sci. 161 (1993) 19^23.
[26] D. Attwood, J.A. Tolley, J. Pharm. Pharmacol. 32 (1980)
761^765.
[27] P.M. Hwang, H.J. Vogel, Biochem. Cell Biol. 76 (1998) 235^
246.
[28] P. Taboada, D. Attwood, J.M. Ruso, M. Garcia, F. Sar-
miento, V. Mosquera, J. Colloid Interf. Sci. 216 (1999)
270^275.
[29] L.M. Varela, C. Rega, M.J. Suarez-Filloy, J.M. Ruso, G.
Prieto, D. Attwood, F. Sarmiento, V. Mosquera, Langmuir
15 (1999) 6285^6290.
[30] A.D. Atherton, B.W. Barry, J. Pharm. Pharmacol. 37 (1985)
854^862.
[31] D. Attwood, V. Mosquera, M. Garcia, M.J. Suarez, F. Sar-
miento, J. Colloid Interf. Sci. 175 (1995) 201^206.
[32] F. Sarmiento, J.L. Lo¤pez-Fonta¤n, G. Prieto, D. Attwood, V.
Mosquera, Colloid Polym. Sci. 275 (1997) 1144^1147.
[33] D. Causon, J. Gettins, J. Gormally, R. Greenwood, N. Na-
tarajan, E. Wyn-Jones, J. Chem. Soc. Faraday Trans. II 77
(1981) 143^151.
[34] S. Yokoyama, Y. Fujino, Y. Kawamoto, A. Kaneko, Chem.
Pharm. Bull. 42 (1994) 1351^1353.
[35] J.M. Ruso, D. Attwood, C. Rey, P. Taboada, V. Mosquera,
F. Sarmiento, J. Phys. Chem. 103 (1999) 7092^7096.
[36] M.F. Fernandez, Biochim. Biophys. Acta 597 (1980) 83^91.
[37] D. Attwood, P. Fletcher, J. Pharm. Pharmacol. 38 (1986)
494^498.
[38] M. Wakita, Y. Kuroda, Y. Fujiwara, T. Nakagawa, Chem.
Phys. Lipids 62 (1992) 45^54.
[39] H. Matsuki, S. Hashimoto, S. Kaneshina, M. Yamanaka,
Langmuir 10 (1994) 1882^1887.
[40] T. Rades, C.C. Muller-Goymann, Int. J. Pharm. 159 (1997)
215^222.
[41] S.Y. King, A.M. Basista, G. Torosian, J. Pharm. Sci. 78
(1989) 95^100.
[42] A. Coutinho, M. Prieto, Biophys. J. 69 (1995) 2541^2557.
[43] H. Matsuki, R. Ishikawa, S. Kaneshina, H. Kamaya, I.
Ueda, J. Colloid Interf. Sci. 181 (1996) 362^369.
[44] M.C. Carey, D.M. Small, J. Lipid Res. 12 (1971) 604^613.
[45] D. Attwood, A.T. Florence, Surfactant Systems, Their
Chemistry, Pharmacy and Biology, Chapman and Hall,
New York, 1983.
[46] A. Felmeister, J. Pharm. Sci. 61 (1972) 151^164.
[47] K. Thoma, K. Albert, Pharmazie 38 (1983) 807^817.
[48] D. Attwood, Adv. Colloid Interf. Sci. 55 (1995) 271^303.
[49] D. Attwood, R. Natarajan, J. Pharm. Pharmacol. 33 (1981)
136^140.
[50] E. Ragg, G. Fronza, J. Chem. Soc. Perkin Trans. II (1982)
1587^1591.
[51] D. Attwood, R. Waigh, R. Blundell, D. Bloor, A. Thevand,
E. Boitard, J.P. Dube's, H. Tachoire, Magn. Reson. Chem.
32 (1994) 468^472.
[52] K. Thoma, M. Arning, Arch. Pharm. 309 (1976) 837^850.
[53] P.J. Missel, N.A. Maser, G. Benedict, C.Y. Young, M.C.
Carey, J. Phys. Chem. 84 (1980) 1044^1057.
[54] J.E. Bennett, G.J. Hill, W.T. Butler, C.W. Emmons, Anti-
microb. Agents Chemother. (1963) 745^750.
[55] H. Rinnert, C. Thirion, G. Dupont, J. Lematre, Biopolymers
16 (1977) 2419^2427.
[56] M.T. Lamy-Freund, V.F.N. Ferreira, S. Schreier, Biochim.
Biophys. Acta 981 (1989) 207^212.
[57] M.T. Lamy-Freund, S. Schreier, R.M. Peitzsch, W.F. Reed,
J. Pharm. Sci 80 (1991) 262^266.
[58] P. Legrand, E.A. Romero, B.E. Cohen, J. Bolard, Antimi-
crob. Agents Chemother. 33 (1992) 2518^2522.
[59] F. Gaboriau, M. Che¤ron, L. Leroy, J. Bolard, Biophys.
Chem. 66 (1997) 1^12.
[60] M.T. Lamy-Freund, V.F.N. Ferreira, S. Schreier, J. Anti-
biot. 38 (1985) 753^757.
[61] M.T. Lamy-Freund, V.F.N. Ferreira, A. Faljoni-Alario, S.
Schreier, J. Pharm. Sci. 82 (1993) 162^166.
BBAMEM 77971 10-11-00 Cyaan Magenta Geel Zwart
S. Schreier et al. / Biochimica et Biophysica Acta 1508 (2000) 210^234230
[62] A. Seelig, R. Gottschlich, R.M. Devant, Proc. Natl. Acad.
Sci. USA 91 (1994) 68^72.
[63] H. Fisher, R. Gottschlich, A. Seelig, J. Membr. Biol. 165
(1998) 201^211.
[64] O.G. Mouritsen, Chem. Phys. Lipids 73 (1994) 3^25.
[65] O.G. Mouritsen, Biochim. Biophys. Acta 1331 (1997) 235^
240.
[66] J.C. Skou, Acta Pharmacol. Toxicol. 10 (1954) 317^324.
[67] P. Seeman, Pharmacol. Rev. 24 (1972) 583^655.
[68] C.O. Abernathy, L. Lukas, H.J. Zimmerman, Biochem.
Pharmacol. 24 (1975) 347^350.
[69] D. Lichtenberg, Biochim. Biophys. Acta 821 (1985) 470^478.
[70] E.A. Dennis, Adv. Colloid Interf. Sci. 26 (1986) 155^175.
[71] S.K. Patra, A. Alonso, F.M. Gon‹i, Biochim. Biophys. Acta
1373 (1998) 112^118.
[72] H. Ha«gerstrand, B. Isomaa, Biochim. Biophys. Acta 1109
(1992) 117^126.
[73] D. Tra«gner, A. Csordas, Biochem. J. 244 (1987) 605^609.
[74] M.S. Bretscher, Science 181 (1973) 622^629.
[75] B. Deuticke, Biochim. Biophys. Acta 163 (1968) 494^500.
[76] M.P. Sheetz, S.J. Singer, Proc. Natl. Acad. Sci. USA 71
(1974) 4457^5561.
[77] A. Iglic, V. Kralj-Iglic, H. Ha«gerstrand, Eur. Biophys. J. 27
(1998) 335^339.
[78] M. Seigneuret, P.F. Devaux, Proc. Natl. Acad. Sci. USA 81
(1984) 3751^3755.
[79] J. Rosso, A. Zachowski, P.F. Devaux, Biochim. Biophys.
Acta 942 (1988) 271^279.
[80] S.L. Schrier, A. Zachowski, P.F. Devaux, Blood 79 (1992)
782^786.
[81] J.Y. Chen, W.H. Huestis, Biochim. Biophys. Acta 1323
(1997) 299^309.
[82] A.J. Verkleij, J. Leunissen-Bijvelt, B. de Kruij¡, M. Hope,
P.R. Cullis, Ciba Found. Symp. 103 (1984) 45^59.
[83] B. Isomaa, H. Ha«gestrand, G. Paatero, Biochim. Biophys.
Acta 899 (1987) 93^103.
[84] H. Tournois, U. Henselheit, J. de Gier, B. de Kruij¡, C.W.
Haest, Biochim. Biophys. Acta 946 (1988) 173^177.
[85] E. Schneider, C.W. Haest, G. Plasa, B. Deuticke, Biochim.
Biophys. Acta 855 (1986) 325^336.
[86] J. Classen, C.W.M. Haest, H. Tournois, B. Deuticke, Bio-
chemistry 26 (1987) 6604^6612.
[87] C. Schwichtenhovel, B. Deuticke, C.W. Haest, Biochim. Bio-
phys. Acta 1111 (1992) 35^44.
[88] A. Chabanel, R.E. Abbott, S. Chien, D. Schachter, Biochim.
Biophys. Acta 816 (1985) 142^152.
[89] F. Basse¤, J. Sainte-Maire, L. Maurin, A. Bienvenue, Eur. J.
Biochem. 205 (1992) 155^162.
[90] R. Regev, G.D. Eytan, Biochem. Pharmacol. 54 (1997)
1151^1158.
[91] P.R. Cullis, A.J. Verkleij, P.H. Ververgaert, Biochim. Bio-
phys. Acta 513 (1978) 11^20.
[92] A.P. Hornby, P.R. Cullis, Biochim. Biophys. Acta 81 (1981)
285^292.
[93] P.R. Cullis, A.J. Verkleij, Biochim. Biophys. Acta 552 (1979)
546^547.
[94] K. Nicolay, R. van der Neut, J.J. Fok, B. de Kruij¡, Bio-
chim. Biophys. Acta 819 (1985) 55^65.
[95] F.A. de Wolf, K. Nicolay, B. de Kruij¡, Biochemistry 31
(1992) 9252^9262.
[96] H. Ha«gerstrand, B. Isomaa, Biochim. Biophys. Acta 982
(1989) 179^186.
[97] P. Maher, S.J. Singer, Biochemistry 23 (1984) 232^240.
[98] M.R. Lieber, Y. Lange, R.S. Weinstein, T.L. Steck, J. Biol.
Chem. 259 (1994) 9225^9234.
[99] A. Spinedi, L. Pacini, C. Limatila, P. Luly, R.N. Farias,
Biochem. J. 278 (1991) 461^463.
[100] P. Boivin, C. Galand, Nouv. Rev. Fr. Hematol. 15 (1975)
589^596.
[101] F.R. Leterrier, F. Rieger, J.F. Mariaud, Biochem. Pharma-
col. 23 (1974) 103^113.
[102] H. Yasuhara, M. Tonooka, K. Kamei, K. Sakamoto, Tox-
icol. Appl. Pharmacol. 79 (1985) 453^460.
[103] S.V.P. Malheiros, E. de Paula, N.C. Meirelles, Biochim.
Biophys. Acta 1373 (1998) 332^340.
[104] S.V.P. Malheiros, N.C. Meirelles, E. de Paula, Biophys.
Chem. 83 (2000) 89^100.
[105] D.W. Lamberts, in: G. Smolin, R.A. Thoft (Eds.), The
Cornea, Little Brown and Co., Boston, MA, 1983, pp.
31^42.
[106] M. Boljka, G. Kolar, J. Vidensek, Br. J. Ophthalmol. 78
(1994) 386^389.
[107] M. Luxnat, H. Galla, Biochim. Biophys. Acta 856 (1986)
274^282.
[108] J.S. Binford Jr., M.S. Rao, V. Pollock, R.C. Malloy,
J. Phys. Chem. 92 (1988) 3522^3526.
[109] M.M. Tedesco, S. Matile, Bioorg. Med. Chem. 7 (1999)
1373^1379.
[110] J.A. Rogers, G.V. Betageri, Y.W. Choi, Pharm. Res. 7
(1990) 957^961.
[111] J.A. Rogers, M.J. Habib, J. Microencapsul. 16 (1999) 141^
151.
[112] W. Schu«tze, C.C. Mu«ller-Goymann, Pharm. Res. 15 (1998)
538^543.
[113] I. Stoye, K. Schroder, C.C. Mu«ller-Goymann, Eur. J.
Pharm. Biopharm. 46 (1998) 191^200.
[114] J. Peuvot, A. Schanck, M. Deleers, R. Brasseur, Biochem.
Pharmacol. 50 (1995) 1129^1134.
[115] M.A. Perillo, D.A. Garcia, Colloids Surf. B, in press.
[116] S. Hartsel, J. Bolard, Trends Pharmacol. Sci. 17 (1996)
445^449.
[117] A. Finkelstein, R. Holz, in: G. Eisenman (Ed.) Membranes,
Lipid Bilayers and Antibiotics, Marcel Dekker, New York,
1973, Vol. 2, pp. 377^408.
[118] B. de Kruij¡, R.A. Demel, Biochim. Biophys. Acta 339
(1974) 59^70.
[119] M.P. Borisova, L.N. Ermishkin, A.Y. Silberstein, Biochim.
Biophys. Acta 553 (1979) 450^459.
[120] Y. Aracava, S. Schreier, R. Phadke, R. Deslauriers, Bio-
phys. Chem. 14 (1981) 325^332.
[121] B. de Kruij¡, W.J. Gerritsen, A. Oerlemans, R.A. Demel,
BBAMEM 77971 10-11-00 Cyaan Magenta Geel Zwart
S. Schreier et al. / Biochimica et Biophysica Acta 1508 (2000) 210^234 231
L.L.M. van Deenen, Biochim. Biophys. Acta 339 (1974)
30^43.
[122] J. Bolard, P. Legrand, F. Heitz, B. Cybulska, Biochemistry
30 (1991) 5707^5715.
[123] J. Barwicz, P. Tancre'de, Chem. Phys. Lipids 85 (1997) 145^
155.
[124] I. Fournier, J. Barwicz, P. Tancre'de, Biochim. Biophys.
Acta 1373 (1998) 76^86.
[125] J. Bolard, M. Seigneuret, G. Boudet, Biochim. Biophys.
Acta 599 (1980) 280^293.
[126] A.R. Balakrishnan, K.R. Easwaran, Biochemistry 32 (1993)
4139^4144.
[127] J. Mazerski, J. Bolard, E. Borowski, Biochim. Biophys.
Acta 1236 (1995) 170^176.
[128] Y. Saka, T. Mita, J. Biochem. 123 (1998) 798^805.
[129] R. Seoane, J. Minones, O. Conde, M. Casas, E. Iribarne-
garay, Biochim. Biophys. Acta 1375 (1998) 798^805.
[130] D. Andreu, L. Rivas, Biopolymers 47 (1998) 415^433.
[131] B. Bechinger, J. Membr. Biol. 156 (1997) 197^211.
[132] Z. Oren, Y. Shai, Biopolymers 47 (1998) 451^463.
[133] K. Matsuzaki, Biochim. Biophys. Acta 1376 (1998) 391^
400.
[134] Y. Shai, Biochim. Biophys. Acta 1462 (1999) 55^70.
[135] B. Bechinger, Biochim. Biophys. Acta 1462 (1999) 157^
183.
[136] R.M. Epand, H.J. Vogel, Biochim. Biophys. Acta 1462
(1999) 11^28.
[137] M. Wu, E. Maier, R. Benz, R.E.W. Hancock, Biochemistry
38 (1999) 7235^7242.
[138] D. Wade, A. Boman, B. Wahlin, C.M. Drain, D. Andreu,
H.G. Boman, R.B. Merri¢eld, Proc. Natl. Acad. Sci. USA
87 (1990) 4761^4765.
[139] E.J. Prenner, R.N.A.H. Lewis, R.N. McElhaney, Biochim.
Biophys. Acta 1462 (1999) 201^221.
[140] G.A. Woolley, B.A. Wallace, J. Membr. Biol. 129 (1992)
109^136.
[141] S.J. Ludtke, K. He, W.T. Heller, T.A. Harroun, L. Yang,
H.W. Huang, Biochemistry 35 (1996) 13723^13728.
[142] G. Schwartz, S. Stankowski, V. Rizzo, Biochim. Biophys.
Acta 861 (1986) 141^151.
[143] M. Ge, J.H. Freed, Biophys. J. 76 (1999) 264^280.
[144] W.R. Veatch, E.R. Blout, Biochemistry 13 (1974) 5257^
5264.
[145] H.H. Paradies, Biochem. Biophys. Res. Commun. 88 (1979)
810^817.
[146] R. Urrutia, R.A. Cruciani, J.L. Barker, B. Kachar, FEBS
Lett. 247 (1999) 17^21.
[147] H.S. Mchaourab, J.S. Hyde, J.B. Feix, Biochemistry 32
(1993) 11895^11902.
[148] S.L. Keller, S.M. Grunner, K. Gawrish, Biochim. Biophys.
Acta 1278 (1996) 241^246.
[149] K. Lohner, E.J. Prenner, Biochim. Biophys. Acta 1462
(1999) 141^156.
[150] J.M. Boggs, B. Tummler, Biochim. Biophys. Acta 1145
(1993) 42^50.
[151] T. Katsu, M. Kuroko, T. Morikawa, K. Sanchika, Y. Fu-
jita, H. Yamamura, M. Uda, Biochim. Biophys. Acta 983
(1989) 135^141.
[152] M.L. Bianconi, A.T. Amaral, S. Schreier, Biochem. Bio-
phys. Res. Commun. 152 (1988) 344^350.
[153] P. van Hoogevest, B. de Kruij¡, Biochim. Biophys. Acta
511 (1978) 397^407.
[154] E. Lissi, M.L. Bianconi, A.T. Amaral, E. de Paula, L.E.B.
Blanch, S. Schreier, Biochim. Biophys. Acta 1021 (1990)
46^50.
[155] E. de Paula, S. Schreier, Biochim. Biophys. Acta 1240
(1995) 25^33.
[156] E. de Paula, S. Schreier, Braz. J. Med. Biol. Res. 29 (1996)
877^894.
[157] A.G. Lee, Biochim. Biophys. Acta 448 (1976) 34^44.
[158] M.R. Eftink, R.K. Puri, M.D. Ghahramani, Biochim. Bio-
phys. Acta 813 (1985) 137^140.
[159] M. Tabak, I.E. Borisevich, Biochim. Biophys. Acta 1116
(1992) 241^249.
[160] S. Desai, T. Hadlock, C. Messani, R. Cha¢tz, G. Strichartz,
J. Pharmacol. Exp. Ther. 271 (1994) 220^228.
[161] G.S.S. Ferreira, D.M. Pe¤rigo, M.J. Politi, S. Schreier, Pho-
tochem. Photobiol. 63 (1996) 755^761.
[162] K.D. Collins, M.W. Washabaugh, Q. Rev. Biophys. 18
(1985) 323^422.
[163] S.A. Tatulian, in: G. Cevc (Ed.) Phospholipid Handbook,
Marcel Dekker, New York, 1993, pp. 511^551.
[164] S. McLaughlin, H. Harary, Biochemistry 15 (1976) 1941^
1948.
[165] E.K. Rooney, A.G. Lee, Biochim. Biophys. Acta 732 (1983)
428^432.
[166] A.G. Lee, S. Schreier, in: G. Gregoriadis (Ed.), Liposome
Technology. Entrapment of Drugs and Other Materials,
CRC Press, Boca Raton, FL, 1993, Vol. 2, pp. 1^25.
[167] M.F. Fernandez, P. Fromherz, J. Phys. Chem. 81 (1977)
1755^1761.
[168] S. Schreier, W.A. Frezzatti Jr., P.S. Araujo, H. Chaimo-
vich, I.M. Cuccovia, Biochim. Biophys. Acta 769 (1984)
231^237.
[169] J. Garcia-Soto, M.S. Fernandez, Biochim. Biophys. Acta
731 (1983) 275^281.
[170] G.R. Strichartz, V. Sanchez, R. Arthur, R. Chafetz, D.
Martin, Anesth. Analg. 11 (1990) 158^170.
[171] J. Miyazaki, K. Hideg, D. Marsh, Biochim. Biophys. Acta
1103 (1992) 62^68.
[172] S.R.W. Louro, O.R. Nascimento, M. Tabak, Biochim. Bio-
phys. Acta 1190 (1994) 319^328.
[173] A. Shibata, K. Ikawa, H. Terada, Biophys. J. 69 (1995)
470^477.
[174] D.A. Garc|¤a, M.A. Perillo, Biochim. Biophys. Acta 1418
(1999) 221^231.
[175] A.G. Oliveira, H. Chaimovich, J. Pharm. Pharmacol. 45
(1993) 850^861.
[176] A.G. Oliveira, I.M. Cuccovia, H. Chaimovich, J. Pharm.
Sci. 79 (1990) 37^42.
[177] A.G. Oliveira, M.S. Nothemberg, I.M. Cuccovia, H. Chai-
movich, J. Phys. Org. Chem. 4 (1991) 19^24.
BBAMEM 77971 10-11-00 Cyaan Magenta Geel Zwart
S. Schreier et al. / Biochimica et Biophysica Acta 1508 (2000) 210^234232
[178] A.G. Oliveira, M.V. Scarpa, H. Chaimovich, J. Pharm. Sci.
86 (1997) 616^620.
[179] F.M. Menger, C.E. Portnoy, J. Am. Chem. Soc. 89 (1967)
4698^4703.
[180] M.L. Bianconi, S. Schreier, J. Phys. Chem. 95 (1991) 2483^
2487.
[181] Y. Katz, J.M. Diamond, J. Membr. Biol. 17 (1974) 69^86.
[182] S. Schreier, A.T. Amaral, A.S. Stachissini, M.L. Bianconi,
Bull. Magn. Reson. 8 (1986) 166^171.
[183] G.R. Strichartz, J.M. Ritchie, in: G.R. Strichartz (Ed.),
Local Anesthetics. Handbook of Experimental Pharmacol-
ogy, Springer-Verlag, Berlin, 1987, Vol. 81, pp. 21^52.
[184] B.D. Anderson, R.A. Conrad, K. Johnson, J. Pharm. Sci.
72 (1983) 448^454.
[185] G.G. Smith, D.R. Kennedy, J.G. Nairn, J. Pharm. Sci. 63
(1970) 712^716.
[186] H. Tomida, T. Yotsuyanagi, K. Ikeda, Chem. Pharm. Bull.
26 (1978) 148^154.
[187] J.M. Patel, D.E. Wurster, Pharm. Res. 8 (1991) 1155^1158.
[188] M.E. Moro, J. Novillo-Fertrell, M.M. Velazquez, L.J. Ro-
driguez, J. Pharm. Sci. 80 (1991) 459^468.
[189] M.J. Habib, J.A. Rogers, Drug Dev. Ind. Pharm. 13 (1987)
1947^1971.
[190] A. Tsuji, E. Miyamoto, M. Matsuda, K. Nishimura, T.
Yamana, J. Pharm. Sci. 71 (1982) 1313^1318.
[191] W.H. Halliwell, Toxicol. Pathol. 25 (1997) 53^60.
[192] M.J. Reasor, Toxicol. Appl. Pharmacol. 97 (1989) 47^56.
[193] W. Buchheim, D. Drenckhahn, R. Lu« llmann-Rauch, Bio-
chim. Biophys. Acta 575 (1979) 71^80.
[194] Y. Matsuzawa, A. Yamamoto, S. Adachi, M. Nishikawa,
J. Biochem. 82 (1977) 1369^1377.
[195] A. Pappu, K.Y. Hostetler, Biochem. Pharmacol. 33 (1984)
1639^1644.
[196] J.K. Seydel, O. Wassermann, Biochem. Pharmacol. 25
(1976) 2357^2364.
[197] U.M. Joshi, P. Rao, S. Kodavanti, B. Coudert, T.M.
Dwyer, H.M. Mehendale, J. Pharmacol. Exp. Pharm. 246
(1988) 150^157.
[198] U. Leli, H. Hauser, Biochim. Biophys. Acta 918 (1987)
126^135.
[199] A. Pappu, P.J. Yazaki, K.Y. Hostetler, Biochem. Pharma-
col. 34 (1985) 521^524.
[200] H. Lu« llmann, R. Lu«llmann-Rauch, Toxicol. Appl. Pharma-
col. 61 (1981) 138^146.
[201] H. Lu« llmann, R. Lu«llmann-Rauch, E.U. Mo«singer, Arz-
neim.-Forsch. Drug Res. 31 (1981) 795^799.
[202] K.Y. Hostetler, L.B. Hall, Proc. Natl. Acad. Sci. USA 79
(1982) 1663^1667.
[203] B.W. Barry, D.I.D. El Eini, J. Pharm. Pharmacol. 28 (1976)
210^218.
[204] C. Vaution, C. Treiner, F. Puisieux, J.T. Carstensen,
J. Pharm. Sci. 70 (1981) 1238^1242.
[205] T. Arnarson, P.H. Elworthy, J. Pharm. Pharmacol. 32
(1980) 381^385.
[206] K.M.S. Fahelelbom, R.F. Timoney, O.I. Corrigan, Pharm.
Res. 10 (1993) 631^634.
[207] S.D. Mithani, V. Bakatselou, C.N. TenHoor, J.B. Dress-
man, Pharm. Res. 13 (1996) 163^167.
[208] J.H. Collet, L. Koo, J. Pharm. Sci. 64 (1975) 1253^1255.
[209] V. Bakatselou, R.C. Oppenheim, J.B. Dressman, Pharm.
Res. 8 (1991) 1461^1469.
[210] S. Miyazaki, H. Inoue, T. Yamahira, T. Nadai, Chem.
Pharm. Bull. 27 (1979) 2468^2472.
[211] D. Ho«rter, J.B. Dressman, Adv. Drug Deliv. Rev. 25 (1997)
3^14.
[212] S.G. Barnwell, T. Laudanski, M. Dwyer, M.J. Story, P.
Guard, S. Cole, D. Attwood, Int. J. Pharm. 89 (1993)
245^250.
[213] F.G. Poelma, R. Brea«s, J.J. Tukker, J.A. Crommelin,
J. Pharm. Pharmacol. 43 (1991) 317^324.
[214] V. Sancho-Chust, M. Bengochea, S. Fabra-Campos, V.G.
Casabo, M.J. Martinez-Camara, A. Martin-Villodre, Arz-
neim.Forsch. 45 (1995) 1013^1019.
[215] P.E. Luner, S.R. Babu, G.W. Radebaugh, Pharm. Res. 11
(1994) 1755^1760.
[216] P.E. Macheras, C.I. Reppas, J. Pharm. Sci. 75 (1986) 692^
696.
[217] H. Sato, H.X. Liu, I. Adachi, M. Ueno, M. Lemaire, I.
Horikoshi, Biol. Pharm. Bull. 17 (1994) 1526^1528.
[218] A. Lindahl, B. Persson, A. Ungell, H. Lennerna«s, Pharm.
Res. 16 (1999) 97^102.
[219] G.S. Gordon, A.C. Moses, R.D. Silver, J.S. Flier, M.C.
Carey, Proc. Natl. Acad. Sci. USA 82 (1985) 7419^7423.
[220] Y. Nakada, N. Awata, Y. Ikuta, S. Goto, J. Pharmacobio-
dyn. 12 (1989) 736^743.
[221] P.A. Baldwin, C.K. Klingbeil, C.J. Grimm, J.P. Longeneck-
er, Pharm. Res. 7 (1990) 547^552.
[222] G.P. Martin, C. Marriott, J. Pharm. Pharmacol. 31 (1981)
754^759.
[223] G.P. Martin, L.M. el-Hariri, C. Marriott, J. Pharm. Phar-
macol. 44 (1992) 646^650.
[224] B.J. van de Heijning, A.M. van den Broek, G.P. van Berge-
Henegouwen, Eur. J. Gastroenterol. Hepatol. 9 (1997) 473^
479.
[225] R.D. Ennis, L. Borden, W.A. Lee, Pharm. Res. 7 (1990)
468^475.
[226] E.K. Anderberg, P. Artursson, J. Pharm. Sci. 82 (1993)
392^398.
[227] H.W. Davenport, Gastroenterology 59 (1970) 505^509.
[228] G.W. Gullikson, W.S. Cline, V. Lorenzsonn, L. Benz, W.A.
Oleson, P. Bass, Gastroenterology 73 (1977) 501^511.
[229] D.A. Whitmore, L.G. Brookes, K.P. Wheeler, J. Pharm.
Pharmacol. 31 (1979) 277^283.
[230] E.J. van Hoogdalem, A.G. de Boer, D.D. Breimer, Pharm.
Ther. 44 (1989) 407^443.
[231] M. Roso¡, A.T.M. Serajuddin, Int. J. Pharm. 6 (1980) 137^
146.
[232] H. Alkan-Onyuksel, K. Son, Pharm. Res. 9 (1992) 1556^
1562.
[233] H. Alkan-Onyuksel, S. Ramakrishnan, H.B. Chai, J.M.
Pezzuto, Pharm. Res. 11 (1994) 206^212.
BBAMEM 77971 10-11-00 Cyaan Magenta Geel Zwart
S. Schreier et al. / Biochimica et Biophysica Acta 1508 (2000) 210^234 233
[234] L.J. Naylor, V. Bakatselou, J.B. Dressman, Pharm. Res. 10
(1993) 865^870.
[235] C.Y. Li, C.L. Zimmerman, T.S. Wiedmann, Pharm. Res. 13
(1996) 907^913.
[236] M.A. Hammad, B.W. Muller, Eur. J. Pharm. Biopharm. 46
(1998) 361^367.
[237] M.A. Hammad, B.W. Muller, Eur. J. Pharm. Sci. 7 (1998)
49^55.
[238] J. Brajtburg, S. Elberg, S.J. Travis, G.S. Kobayashi, J.
Bolard, Antimicrob. Agents Chemother. 38 (1994) 300^
306.
[239] L.C. Souza, R.C. Maranha‹o, S. Schreier, A. Campa,
J. Antimicrob. Chemother. 32 (1993) 123^132.
[240] J.S. Dangi, S.P. Vyas, V.K. Dixit, Drug. Dev. Ind. Pharm.
24 (1998) 631^635.
[241] P. Tancre'de, J. Barwicz, S. Jutras, I. Gruda, Biochim. Bio-
phys. Acta 1030 (1990) 289^295.
[242] J. Barwicz, S. Christian, I. Gruda, Antimicrob. Agents Che-
mother. 36 (1992) 2310^2315.
[243] C. Petit, M. Cheron, V. Joly, J.M. Rodrigues, J. Bolard, F.
Gaboriau, J. Antimicrob. Chemother. 42 (1998) 779^785.
[244] D.D. Lasic, Nature 355 (1992) 279^280.
[245] B.G. Yu, T. Okano, K. Kataoka, G. Kwon, J. Control.
Release 53 (1998) 131^136.
[246] V.P. Torchilin, J. Microencapsul. 15 (1998) 1^19.
[247] M. Yokoyama, T. Okano, Y. Sakurai, H. Ekimoto, C.
Shibazaki, K. Kataoka, Cancer Res. 51 (1991) 3229^3236.
[248] M.J. Lawrence, S.M. Lawrence, D.L. Barlow, J. Pharm.
Pharmacol. 49 (1997) 594^600.
[249] S.P. Vyas, J. Jaiteli, P. Kanamyia, Pharmazie 52 (1997)
259^267.
[250] V. Weissig, K.R. Whiteman, V.P. Torchilin, Pharm. Res. 15
(1998) 1552^1556.
[251] R. Hunter, F. Strickland, F. Ke¤zdy, J. Immunol. 127 (1981)
1244^1250.
[252] A.V. Kabanov, V.P. Chekhonin, V.Y. Alakhov, E.V. Ba-
trakova, A.S. Lebedev, N.S. Melik-Nubakov, S.A. Arzba-
kov, A.V. Levashov, G.V. Morosov, E.S. Severin, V.A.
Kabanov, FEBS Lett. 258 (1989) 343^345.
[253] E.V. Batrakova, H.Y. Han, D.W. Miller, A.V. Kabanov,
Pharm. Res. 15 (1998) 1525^1532.
[254] G.S. Kwon, T. Okano, Pharm. Res. 16 (1999) 597^600.
[255] S.B. La, T. Okano, K. Kataoka, J. Pharm. Sci. 85 (1996)
85^90.
[256] T. Kidchob, S. Kimura, Y. Imanishi, J. Control. Release 51
(1998) 241^248.
[257] M. Ramaswamy, X. Zhang, H.M. Burt, K.M. Wasan,
J. Pharm. Sci. 86 (1997) 460^464.
[258] S.Y. Kim, I.G. Shin, Y.M. Lee, Biomaterials 20 (1999)
1033^1042.
[259] J.E. Chung, M. Yokoyama, M. Yamato, T. Aoyagi, Y.
Sakurai, T. Okano, J. Control. Release 62 (1999) 115^127.
[260] N. Jayasuriya, S. Bosak, S.L. Regen, J. Am. Chem. Soc.
112 (1990) 5851^5854.
[261] R.E. Co¡man, D.O. Kildsig, Pharm. Res. 13 (1996) 1460^
1463.
[262] G.K. Poochikian, J.C. Cradock, J. Pharm. Sci. 68 (1979)
728^732.
[263] J. Truelove, R. Bawarshi-Nassar, N.R. Chen, A. Russain,
Int. J. Pharm. 19 (1984) 17^25.
[264] K.S. Raghavan, G.A. Nemeth, D.B. Gray, M.A. Russain,
Pharm. Dev. Technol. 1 (1996) 231^238.
[265] A.R. Souza, R. Najjar, S. Glikmanas, S.B. Zyngier, J. In-
org. Biochem. 64 (1996) 1^5.
[266] M.B. Zughul, M. Omari, A.A. Badwan, Drug. Dev. Ind.
Pharm. 22 (1996) 1013^1019.
[267] V. Srinivas, D. Balasubramanian, Langmuir 14 (1998)
6658^6661.
[268] B.D. Anderson, R.A. Conrad, K.E. Nuth, S.L. Nail,
J. Pharm. Sci. 74 (1985) 375^381.
[269] J.L. Murtha, H.Y. Ando, J. Pharm. Sci. 83 (1994) 1222^
1228.
[270] D.G. Mu«ller, V.J. Stella, A.P. Lo«tter, Int. J. Pharm. 86
(1992) 175^186.
[271] R.B. Greenwald, A. Pendri, C.D. Comover, H. Zhao, Y.H.
Choe, A. Martinez, K. Shum, S. Guan, J. Med. Chem. 42
(1999) 3657^3667.
[272] F. Kopecki, Pharmazie 51 (1996) 135^144.
[273] L.M.S. Martins, E.M. Mamizuka, A.M. Carmona-Ribeiro,
Langmuir 13 (1997) 5583^5587.
[274] J.E. Scurlock, B.M. Curtis, Anesthesiology 54 (1981) 265^
269.
BBAMEM 77971 10-11-00 Cyaan Magenta Geel Zwart
S. Schreier et al. / Biochimica et Biophysica Acta 1508 (2000) 210^234234
